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ABSTRACT 
 
 
The development of novel therapies for cancer and other diseases is an area of 
enormous research effort due to the growing need for better patient outcomes. As 
such, not only is the chemical synthesis of new drugs and adjuvants required, but 
ways to improve drug delivery also need to be explored. Accordingly, there has been 
much recent effort towards the synthesis and the biological evaluation of bacterial 
cell wall components as immunomodulatory compounds. To this end, trehalose 
glycolipids (TGs), which have been isolated from bacteria of the Mycobacteria 
family, are of significant interest, due to their anti-tumour and adjuvant activities.  
 
In this thesis, the efficient synthesis of trehalose monoesters (TMEs) was 
investigated and the ability of these monoesters to activate macrophages via Mincle 
was studied and compared to the activities of their trehalose diester (TDE) 
counterparts. In this way, a better understanding of how TG structure influences 
biological activity was explored. Liposomes containing a representative TG (the C26 
TDE) were also synthesised, with the objective being to explore whether TG-
liposomes could be used as improved drug delivery vehicles. To meet these overall 
objectives, TGs in solution, as well as TG incorporated into liposomes, were tested 
for their ability to activate macrophages derived from both C57BL/6 and Mincle-/- 
mice, whereby the Mincle receptor is a known receptor for TDEs.  
 
In the TME studies, an optimised synthesis of the monoesters was developed. The 
ability of the TMEs to active macrophages was explored and, for the first time, it 
was observed that TMEs have similar biological activities to TDEs. In the TG-
liposome studies, a variety of liposomes containing different concentrations of 
phosphatidylcholine (PC) as well as the C26 TDE was prepared, so as to explore 
how differences in these two constituent parts influence the activation of 
macrophages. From this work, it was observed that increasing concentrations of TG 
in the liposome and increasing concentrations of liposomes gave increased 
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macrophage activation. A concentration of PC above 200 !M also led to 
macrophage activation, and non-specific cell death was observed at time points > 48 
h (for the wild type macrophages) and at time points " 48 h for the Mincle-/- 
macrophages. Thus, in the case of the TG liposomes, macrophage activation is 
independent of Mincle, which was unusual as macrophage activation in the case of 
the individual TGs was dependent on this receptor.  
 
Taken as a whole, these results pave the way for further investigations into utilising 
TGs in the treatment of diseases. In particular, this work provided insight into the 
requirement of TG/Mincle binding for improved TGs as potential adjuvants. 
Moreover, these studies demonstrated that the incorporation of TGs into liposomes 
leads to enhanced macrophage activation and therefore, potentially enhanced 
phagocytosis by these immune cells. Accordingly, TG-liposomes may find future 
application as drug delivery vehicles, in diseases where macrophages play a 
prominent role. 
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CHAPTER 1: 
 
BACKGROUND 
 
 
1.1 Mycobacteria in disease 
 
The interactions between humans and bacteria are among the most diverse investigative 
fields in the medical sciences. Although chronic infections due to bacteria have 
contributed to their negative image, there are also many bacteria which can be beneficial 
to humans, such as intestinal microflora and commensal microbes found on the body’s 
surface.1 As the presence of bacteria often stimulates the immune system, the use of 
bacteria in the treatment of diseases has also been explored.  
 
Before there was much knowledge and understanding of how the immune system acts 
on tumours, a few medical doctors reported that infection could cause tumour 
regression.2 These observations date back to the 1800’s when German physicians W. 
Busch and F. Fehleisen separately noticed tumour regression in cancer patients who 
were infected by erysipelas. Fehleisen later determined that erysipelas is caused by 
Streptococcus pyrogenes.1  
 
A short time later, a New York surgeon, William Coley, observed that malignant 
tumours regressed in patients who were suffering from bacterial infections.3 Coley 
treated bone and soft tissue sarcoma patients with erysipelas and noted infection-
associated tumour regression.1 He then experimented with treatments involving live 
Streptococci and while patient outcomes were encouraging, systemic Streptococcus 
infection was fatal. Subsequently, Coley used heat-killed Streptococcus organisms with 
heat-killed Serratia marcescens, which became a bacterial vaccine known as “Coley’s 
toxin”.4 Over the next 40 years, Coley treated more than 1000 cancer patients with 
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bacteria or bacterial products, which led to a high success rate in the treatment of 
sarcomas and other malignancies, including carcinomas (e.g. breast and renal cancer), 
lymphomas and melanomas. However, his work was criticised as his results could not 
be reproduced due to poor documentation and the follow-up of patients, and 
inconsistencies in the preparation of the toxins. There were thirteen different toxin 
preparation methods reported, which all varied in effectiveness. With the emergence of 
chemotherapy and radiotherapy, Coley’s work thus gradually fell out of favour.  
 
Today, however, it is well established that bacteria, as well as bacterial components, can 
activate the immune system5 and can be used in the treatment of disease. There are 
several examples of attenuated bacteria that have been used in vaccines. For example, 
Salmonella typhi is used in the Ty21a vaccine to vaccinate against typhoid fever,6 Vibrio 
cholerae is used in CVD 103-HgR to vaccinate against cholera,6 and Mycobacterium 
tuberculosis in Calmette-Guérin (BCG) for vaccination against tuberculosis.7 Another 
prominent example is the use of attenuated Mycobacterium tuberculosis (M. tb), which 
forms a key component in Freund’s complete adjuvant (FCA) system. FCA is effective 
in stimulating cell-mediated immunity and has thus been used in a number of animal 
models of disease. FCA has also been found to have potential in the prevention of 
juvenile-onset diabetes in mouse models,8 as well as in Parkinson’s disease in rat 
models,9 however, the adjuvant cannot yet be applied in human studies due to issues 
with toxicity.10 To this end, there has been much interest in determining how the 
individual components of the mycobacterial cell wall influence the immune response. 
 
Of particular interest to my Masters research is exploring the potential of trehalose 
glycolipids in the treatment of disease. Complex trehalose glycolipids, the trehalose 
dimycolates (TDMs), are found in the outer cell wall of M. tb and related mycobacteria 
and have been found to be highly immunostimulatory. Indeed, the Th1 and Th17 
immune response by FCA has recently been attributed to TDM and peptidoglycan,11 
while the CAF01 adjuvant system, which consists of a cationic liposome containing a 
synthetic trehalose glycolipid (trehalose dibehenate, TDB) and a recombinant M. Tb 
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fusion protein has shown promise in the treatment of tuberculosis.12 TDM is the most 
abundant lipid produced by virulent M. tb, yet despite this, the mechanism of activity of 
the glycolipid in the context of tuberculosis pathogenicity still remains puzzling. This is 
due in part to the glycolipid’s ability to change from non-toxic to highly toxic depending 
on the aggregation state of the glycolipids.13 The exact structure of the glycolipid has 
also been found to affect the specific immune reponse.13 
 
 
1.2 Trehalose Glycolipids: The Trehalose 6,6´-diester family 
 
Trehalose glycolipids were initially discovered as an important factor in the 
mycobacterial cell wall that contributes to the bacteria’s virulence.14 In the early 1950s, 
Bloch found that virulent strains of mycobacteria contained a material called “cord 
factor,” which was essential for the pathogenesis of mycobacteria.15 In subsequent years, 
cord factor was found to be a class of compounds called trehalose [$-D-glucosyl-(1%1)- 
$-D-glucose] dimycolates.16,17 A variety of trehalose glycolipids have subsequently been 
isolated from bacteria such as Mycobacteria and Corynebacteria, and many of these 
glycolipids exhibit important and often different biological properties.14 
 
The family of trehalose glycolipids (Figure 1) is divided into two classes: 6,6´-trehalose 
diesters [including fatty acid esters (TDEs, 1), trehalose dicorynomycolates (TDCMs, 2) 
and trehalose dimycolates (TDMs, 3)] and 2,3-trehalose diesters.14 TDMs are the most 
widely studied of the trehalose glycolipids, and are characterised by the presence of a 
mycolic acid and a trehalose moiety.14 The mycolic acid contains at least two chiral 
centres (!- and #- to the carboxylic acid), both with R-configuration.18 In mycolic acids 
(4), the lipid chain positioned !- to the carboxylate is called the alpha- (!-) branch, 
while the other portion is known as the meromycolate branch. In different TDMs, only 
the !-branch differs in the number of carbon atoms, however, the meromycolate is more 
variable and contains different functional groups.19 These differences allow mycolic 
acids to be classified into two groups: the !-mycolates, which do not contain 
  18 
oxygenated functional groups in the meromycolate branch, and the oxygenated 
mycolates. The most common !-mycolates are those which have cis cyclopropane 
groups on the meromycolate branch (4A), while for the oxygenated meromycolates, 
those containing keto- (4B) or epoxy-groups (4C) are the most common.20 
 
Today, there are still an extraordinary number of novel trehalose glycolipids being 
discovered, including maradolipids, a much shorter glycolipid found in the dauer larvae 
of C. elegans in 2010.21 The sheer wealth of trehalose glycolipids found within 
biological systems, however, has its disadvantages. For example, TDM extracts from 
mycobacteria alone contain over 500 different compounds which differ in chain length 
and functional groups (e.g. ketones, cyclopropanes, methoxy groups, Figure 1).21 As a 
consequence, the immunological profile of distinct compounds is difficult to discern. In 
view of this, much effort has been placed on obtaining homogenous materials through 
chemical synthesis so that the biological profile of each individual glycolipid can be 
better understood. 
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Figure 1. The family of trehalose glycolipids. 
 
 
1.2.1 Synthesis of Trehalose diesters (TDEs) 
 
The simplest glycolipids found in the trehalose 6,6´-diester family are trehalose diesters 
of fatty acids (TDEs, e.g. 1, Figure 1). TDEs are differentiated by their lipid length in 
the $ branch of the mycolic acid. It is only in recent years that these compounds have 
been discovered in the animal kingdom,21 although they have been synthesised and 
evaluated for anti-tumour22 and anti-bacterial activities23 since the late 1970’s. Of the 
TDEs, the most well-studied is the C22 derivative, trehalose dibehenate (TDB, n = 20, 
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Figure 1), which has been found to bind and activate macrophages (M$) in the same 
way as the more complex TDMs.11 
 
Several different approaches have been developed over time for the synthesis of TDEs. 
One of the first synthetic methods, reported in 1973 by Toubiana et al., involved the use 
of a potassium carbonate mediated trans-esterification of fatty acid methyl esters with 
trehalose.24 Although this reaction successfully allowed for the formation of esters, it 
proved unselective and mixtures of mono-, di- and tri-esters were also formed. Others 
have reported on the reaction of 6,6´-di-O-tosyl-trehalose with the potassium salt of 
palmitic acid,25 though a major drawback of this methodology is the formation of 3,6-
anhydro-trehalose products and other by-products that are hard to separate from the 
desired TDE. This methodology was later improved by Toccane26 and Toubiana et al.32 
who proposed the use of another starting material, 6,6´-dihalo-6,6´-dideoxy-trehalose, 
for the synthesis of TDEs to eliminate the occurrence of these anhydro-trehalose side 
products. It has also been suggested that the esterification reaction en route to the 
synthesis of TDEs can be improved through the use of benzyl-protected trehalose 
(2,2´,3,3´,4,4´-hexa-O-benzyl-trehalose) as an intermediate,27 however, our group 
observed that subsequent removal of the benzyl groups from glycolipids with a fatty 
acid chain of more than 18 carbon atoms was difficult.28 Here, hydrogenation proved to 
be sluggish, which has also been reported previously,29 and was likely due to the poor 
solubility of these amphiphilic compounds. The reaction of trehalose with fatty acids in 
the presence of diisopropyl azodicarboxylate (DIAD) and triphenyl phosphine (PPh3) 
has also been reported for the synthesis of TDEs.30 Here, unprotected trehalose and 
palmitic acid were subjected to a Mitsunubo reaction to give 6,6´-trehalose dipalmitate 
in 59% yield.30 In later studies, the scope of this methodology was extended to the 
synthesis of more complex TDMs.31 
 
The use of TMS-protected trehalose (2,2´,3,3´,4,4´-hexa-O-trimethylsilyl-trehalose) has 
proven to be a useful intermediate in the synthesis of a variety of TDEs. TMS-protected 
trehalose is appealing because of the ease with which the TMS groups can be removed 
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after esterification. Toubiana and co-workers initially synthesised hexa-trimethylsilyl 
trehalose in two steps from commercially available trehalose,32 and later Johnson 
developed a two-step one-pot synthesis of this key intermediate,33 which was 
subsequently used for the formation of trehalose dipalmitate.34 Datta et al. have also 
used similar methodology, whereby the amount of carboxylic acid was manipulated to 
give both the mono- and di-esters in good yields,35 while Khan et al. used this 
intermediate in the synthesis of TDEs of various lipid lengths.28 
 
The chemoenzymatic synthesis of fatty acid mono- and di-esters of trehalose has also 
been explored. There is great interest in chemoenzymatic syntheses due to the ability to 
regio- and stereo-selectively transform saccharides. The most common enzyme used in 
trehalose acylation is a lipase from Candida antarctia. Oosterom et al. reported the use 
of this lipase for the synthesis of the 6-butanoyl ester of trehalose in tert-butyl alcohol36 
and Part et al. have also used this lipase for yielding trehalose 6,6´-vinyladipoyl 
diesters.37 All enzymatic TDE synthesis to date, however, have contained lipids that are 
short in length. 
 
 
1.2.2  Biological activity of TDEs 
 
TDEs have been found to exhibit a number of interesting biological properties, 
including anti-cancer activity and an ability to confer protection against pathogenic 
challenge.14,38,39 That said, there is limited knowledge about the underlying cause of the 
stated biological effects, which in part is due to inconsistencies across the various 
experimental models. In the case of the anti-cancer activity of TDEs, it is not well 
understood how the structure of the TDE affects their tumoricidal properties, though it 
was observed that at least 10 carbons on the acyl chain were required to induce anti-
tumour activity in Ehlrich ascites carcinoma.22 Moreover, the addition of 
lipopolysaccharide (LPS), a major component of the outer membrane of Gram-negative 
bacteria, has been found to enhance the anti-tumour activities of linear TDEs in in vivo 
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tumour studies,40 and the presence of an oil-vehicle also appears to enhance the anti-
tumour response.41 No insight was provided as to why oil/water emulsions increase the 
anti-tumour activity of TDEs, though later studies with TDMs has led to the hypothesis 
that TDMs in oil/water leads to the formation of monolayers, and it is these monolayers 
that are cytotoxic.42 With regard to the ability of TDEs to confer protection against 
pathogenic organisms, neither the C16 and C22 linear TDEs conferred protection 
against Klebsiella pneumoniae and Listeria monocytogenes,23 however, the C16 TDE 
did confer protection when tested on Schistosoma mansoni,38 and Salmonella typhi and 
Salmonella typhimurium.39 
 
In an attempt to better understand the biological activities of TDEs, and in particular 
how the TDE lipid length affects the innate immune response of M$s, Khan et al. 
explored the ability of a series of TDEs to activate Bone marrow derived macrophages 
(BMMs). Here, BMMs were stimulated by TDEs varying in lipid chain length (C4-C26) 
and the supernatant was analysed for NO, interleukin (IL)-6 and IL-1# production. From 
this work it was demonstrated that a lipid length of more than 18 carbon atoms was 
required for M$ activation.28  
 
 
1.2.3 Synthesis of Trehalose Dimycolates (TDMs) 
 
The complexity of TDMs has made their synthesis challenging and to date, only a few 
groups have embarked upon this endeavour. Baird and co-workers have been leaders in 
this field and have focused on the synthesis of various mycolic acids en route towards 
the synthesis of TDMs,43-45 and more recently, have synthesised individual TDMs.46 To 
synthesise the mycolic acid portion of TDM, Baird and co-workers used a variety of 
different approaches, however, a key strategy in their overall route included a Fráter-
Seebach alkylation for the instalment of the !-branch of the mycolic acid. In their first 
synthesis of the !-mycolic acid, Baird and co-workers reported a low yield of 31% for 
their Fráter-Seebach alkylation when using tetracosanyl iodide (5 % 6, Scheme 1),43 
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while in later syntheses, the group developed a chain-elongation strategy47 involving an 
!-alkylation using allyl iodide, followed by ozonolysis and a Julia-Kocienski reaction. 
To complete the synthesis of the !-alkyl-#-hydroxy fragment,43 the secondary alcohol 
of the Fráter–Seebach alkylation product 6 was protected with an acetate group, the tert-
butyldiphenylsilyl (TBDPS) group was deprotected, and the resulting primary hydroxyl 
oxidised to give aldehyde 7, the core fragment of the target mycolic acid. More recently, 
Khan et al. reported on the use of long chain allylic iodides in Fráter-Seebach 
alkylations, which allowed for improved yields for the !-alkylation step.47 
 
MeO (CH2)10OH
OHO
MeO (CH2)10OSiPh2But
OHO
(CH2)23CH3
MeO (CH2)9CHO
OAcO
(CH2)23CH3
i ii - iv
65 7  
 
Scheme 1. Synthesis of the !-alkyl-#-hydroxy fragment; Reagents and conditions: 
(i) LDA, CH3(CH2)23I, HMPA, 31%; (ii) Ac2O, pyridine, 86%; (iii) 
TBAF, 75%; (iv) PCC, 95%.  
 
For the synthesis of the meromycolate branch of the mycolic acid, Baird and co-workers 
employed a number of different strategies depending on the functional groups to be 
incorporated.45,48-50 A representative example of the synthesis of an !-mycolate is given 
in Scheme 2. Here, aldehyde 8 was subjected to a Wittig reaction with 
MeO2C(CH2)10CH=PPh3, followed by reduction of the resulting ester to the alcohol, 
hydrogenation of the double bond and oxidation of the alcohol to give aldehyde 9.51 
Reaction of ester 10 with thiazole 11 and subsequent oxidation of the resulting thioether 
then gave sulfone 12, which was reacted with aldehyde 9 in a Julia-Kocienski reaction 
to give alkene 13 as a mixture of E and Z isomers. Reduction of ester 13 using lithium 
aluminium hydride (LiAlH4), followed by hydrogenation of the alkene gave the 
dicyclopropyl-alcohol 14. Reaction of alcohol 14 with thiazole 11, followed by 
oxidation of the resulting thioether led to sulfone 15, which was then reacted 
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with aldehyde 7 (from Scheme 1) in a further Julia-Kocienski reaction to form methyl 
ester 16. Finally, hydrogenation of the alkene in 16, followed by hydrolysis of the 
acetate and methyl esters led to the !-mycolic acid 17. 
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Scheme 2. Synthesis of the meromycolate branch of the mycolic acid; Reagents and 
conditions: (i) MeO2C(CH2)11PPh3I, NaOMe, DMF, 70%; (ii) LiAlH4, 
THF, 92%; (iii) N2H4, NaIO4, AcOH, CuSO4, i-PrOH, 85%; (iv) PCC, 
CH2Cl2, 93%; (v) PPh3, DEAD, 77%; (vi) mCPBA, CH2Cl2, 82%; (vii) 
LiHMDS; (viii) 9, 43% over two steps; (ix) LiAlH4; (x) NH2NH2, NaIO4, 
CuSO4, AcOH, i-PrOH, 77% over two steps; (xi) 11, PPh3, DEAD, 66%; 
(xii) mCPBA, CH2Cl2, 62%; (xiii) LiHMDS, then 7, 37%; (xiv) 
dipotassium azodicarboxylate, CH3COOH, THF, 60%; (xv) LiOH, THF, 
H2O, MeOH, 45 °C. 
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Baird and co-workers then used this mycolic acid to prepare an !-TDM (Scheme 3). 
The hydroxyl group of the mycolic acid was first protected as a TBDMS ether (%18) 
and 18 was subsequently coupled to hexa-trimethylsilyl-trehalose 19. Using this 
approach, both di-esterified and mono-esterified products were obtained in good yield, 
and these were then deprotected in two steps to obtain TDM 22 and trehalose 
monomycolate (TMM) 23.46 
 
 
  27 
O
O
TMSO
TMSO
TMSO
OTMS
OTMS
OTMS
HO
OH
OR OH
TBDMSO
R'
O
O
O
TMSO
TMSO
TMSO
OTMS
OTMS
OTMS
O
O
O
R
TBDMSO
R'
O
R
O
R'
OTBDMS
O
O
TMSO
TMSO
TMSO
OTMS
OTMS
OTMS
O
OH
O
R
TBDMSO
R'
O
O
O
HO
HO
HO
OH
OH
OH
O
O
O
R
HO
R'
O
R
O
R'
OH
O
O
HO
HO
HO
OH
OH
OH
O
OH
O
R
HO
R'
O
R' = -(CH2)23CH3
R = (CH2)14 (CH2)11 -CH3(H2C)19
!"TDM
18 19
20 21
22 23
i
ii, iii ii, iii
 
Scheme 3. Synthesis of !-TDM 22 and TMM 23; Reagents and conditions: (i) 
EDCI, 4-DMAP, CH2Cl2, 4 Å MS, 6 d, rt, 20, 51%; 21, 42%; (ii) TBAF, 
THF, 5 °C, 1 h; (iii) pyridine, THF, HF–pyridine complex, 43 °C, 17 h, 
then aq. NaHCO3, 22, 56%; 23, 62%; over two steps. 
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1.2.4 Biological activity of TDMs 
 
Heterogeneous mixtures of TDMs isolated from Mycobacterium have been tested for 
their biological activities and have been found to possess a number of biological 
properties including anti-tumour activity,52 adjuvant activity,53 anti-bacterial activity,39 
and the ability to induce granuloma formation,54 as well as angiogenesis.55 It is only 
very recently that homogenous trehalose mono- and dimycolates have been tested for 
biological activity. Synthetic !-TDM 22 was found to activate mouse RAW 264.7 M$s 
to produce TNF (tumor necrosis factor alpha)-! and MCP (monocyte chemoattractant 
protein)-1 in about three-fold excess compared to a commercial sample of TDM.46 
Synthetic TMM 23 on the other hand was found to activate M$s at a lesser extent, and 
the production of TNF-! and MCP observed was half of that for commercial TDM. This 
finding is particularly interesting as it illustrates how the specific structure of the 
trehalose glycolipid can influence biological activity. 
 
 
1.3 The TDM Receptor: Macrophage Inducible C-type Lectin (Mincle) 
 
It is widely known that bacteria trigger M$ activation through recognition by the innate 
immune system56 and that M$s have pattern recognition receptors (PRRs) for microbial 
ligands.57 These ligands contain pathogen associated molecular patterns (PAMPs), 
which can be recognised by PRRs. Some PRRs include Toll-like receptors (TLR), 
Nucleotide binding oligomerisation domain (NOD)-like receptors, and C-type lectins 
(such as Dectin-1, Dectin-2, and Mincle).57,58 These ligand-receptor interactions decode 
pathogen information by triggering distinct signalling pathways to differentially activate 
APCs and direct a response which is specific for the invading bactieria.59  
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1.3.1 Binding Mincle and Intracellular signalling 
 
In 2009, the receptor for TDM was identified as Macrophage Inducible C-type Lectin 
(Mincle). Mincle (also called CLEC4E) is a C-type lectin with an extracellular Ca2+-
dependent carbohydrate domain that contains a mannose binding motif.60 Mincle is 
expressed at low levels on several cell types including monocytes, M$s, neutrophils, 
myeloid dendritic cells (DCs) and some subsets of B cells,61 but is up-regulated in 
response to a number of signals, including the activation of TLRs, or through an auto 
amplification loop initiated by Mincle-ligands,62 such as the trehalose glycolipids 
themselves.63  
 
Lang and co-workers used various BMM knockout models to determine that C-type 
lectins, rather than TLRs, recognise the glycolipids TDM and TDB.59 BMMs were 
tested for their ability to respond to TDM and TDB, with activation of BMMs being 
measured by nitric oxide (NO) and cytokine production. TLRs signal via the adaptor 
protein MyD88 to induce T helper (Th) 1 directing cytokines, although certain C-type 
lectin receptors use the kinase Syk to direct Th-17 differentiation.59 To determine the 
pathway required for TDM and TDB mediated cell activation, TDM and TDB 
stimulated MyD88-/- and Syk-/- BMMs were compared to stimulated wild-type BMMs. 
Although MyD88-/- BMMs retained their normal response, Syk-/- BMMs elicited no 
response. In a similar manner, the myeloid cell-specific adaptor protein, Card9, was 
required for the TDM stimulated BMM response, and also the downstream proteins 
Bcl10 and Malt1. The !-glucan receptor Dectin-1, which had previously been linked to 
antigen presenting cell responses to whole mycobacteria, was also excluded as the TDM 
receptor using Dectin-1-/- BMMs. As a large number of myeloid cell receptors which 
activate Syk are associated with adaptor proteins Dap12 or FcR#, the requirement for 
these proteins was tested. FcR#, but not Dap12, was found to be essential in linking 
TDM and TDB recognition to M$ activation via the Syk-Card9 signalling pathway.59 In 
a later study, Mincle-/- mice were used to establish that this FcR#-associated receptor is 
crucial for TDM induced M$ activation.11  
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1.3.2 Induction of the Th-1/Th-17 immune response by Mincle 
 
The overall effect of TDM or TDB binding and activation of Mincle is the induction of a 
Th-1 and Th-17 immune response (Figure 2).11 Stimulation of Mincle through TDM 
activates this signaling pathway to induce the expression of many different 
proinflammatory cytokines (e.g. IL-1#, IL-6, TNF-! and IFN-&), chemokines (e.g. 
MCP-1 and MIP-1!) and the release of small molecule cytotoxic mediators, such as 
iNOS.59,64 Importantly, the release of IL-12 by marcophages enhances Th-1 
differentiation, while the production of IL-6, TGF-#, IL-23 and IL-1# favours the 
development of a Th-17 response. This Th1/Th17 response along with the up-regulation 
of co-stimulatory molecules (CD80, CD86) and Major histocompatibility complex 
(MHC)-II induce further expression of Mincle on APCs and the activation of the early 
adaptive immune response, which is required for the development of protective T cell 
immunity. Indeed, the capability of Freund’s complete adjuvant and the CAF01 
liposomes to induce Th1 and Th17 immunity in mice has been attributed to the ability of 
trehalose glycolipids to activate the FcR&-Syk-Card9 pathway.59,65 
 
 
 
Figure 2. The Th-1/Th-17 immune response by Mincle 
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1.3.3 Ligands for Mincle 
 
At present, there is much interest in better defining the ligands for Mincle. Mincle has 
been shown to bind to mannose containing glycolipids from C. albicans and Malassezia 
species with affinity for !-mannose geometry,66,67 however, it does not recognise !-1,2-
oligomannose-containing glycolipids from the M. tb cell wall or any other cell wall 
components apart from TDM and its derivatives.11 Studies by Ishikawa et al. in 200958 
established that the 1,1-!-linked glucose disaccharide (trehalose) motif is essential for 
the recognition of mycobacteria. As TDB is also capable of activating Mincle 
expressing cells,11 yet neither trehalose alone or the corresponding lipid are able to 
activate, this suggests that both the sugar head group and the lipid are required for the 
activation of Mincle.68  
 
 
1.3.4 Crystal Structure of Mincle 
 
Very recently, the first crystal structures of Mincle were solved by two independent 
research groups.69,70 Both groups solved the structure with citric acid bound to the 
carbohydrate recognition domain (CRD), while Feinberg et al. also solved the crystal 
structure with trehalose bound. 
 
Feinberg et al. used X-ray crystallography, mutagenesis, and competition studies to 
reveal an extended ligand-binding site in Mincle.69 This binding site was found to 
interact with both the sugar head group and acyl portions of the glycolipid. 
Characterisation of the Mincle CRD was achieved by comparison of mouse, human and 
cow Mincle, which revealed that all species had close sequence similarity throughout 
the polypeptides, including in the C-terminal CRD. Crystals of expressed CRD were 
then analysed by X-ray crystallography and solved by molecular modelling to reveal 
that the Mincle polypeptide assumes an overall fold similar to other C-type CRDs. 
When generated in the presence of citric acid, it is also interesting to note the 
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dissimilarity between Mincle and other C-type lectins at the Ca2+ binding site. In the 
conserved Ca2+ binding site that serves as the primary sugar-binding region, there are 
normally five amino acid side chains that form the divalent cation-binding site, yet 
Mincle only has three chains, which coordinate to Ca2+.  Generation of the Mincle CRD 
crystals in the presence of trehalose, however, resulted in a significant change in the 
organisation of the crystal so that the trehalose complex has five side chain ligands for 
the conserved Ca2+ ion. This change in conformation and lattice packing was attributed 
to the presence of saturating trehalose as both crystal structures were obtained under the 
same conditions. Trehalose-bound Mincle (Figure 3) also assumes a conformation that is 
observed in crystal structures of unrelated proteins, for example, trehalose/maltose 
binding protein from Thermococcus litoralis, M. tb antigen 85B, and the C-terminal lobe 
of bovine lactoferrin.69 Here, the two glucose residues are arranged in such a way that 
one glucose residue brings the second glucose residue into contact with a greater surface 
area of the protein to form a secondary binding site. In this secondary binding site, the 
glucose 2-OH forms part of a hydrogen-bonding network that accepts a hydrogen bond 
from Arg182 and donates to Glu135 to ultimately bridge these two side chains. Arg182 
is also important because it is packed against C3 of the glucose residue in the secondary 
binding site. The secondary binding site observed in the crystal structure thus suggests 
that this site may function as part of the binding mechanism for TDM. 
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Figure 3. Mincle-trehalose disaccharide interactions at both the primary and 
secondary binding sites. This research was originally published in The 
Journal of Biological Chemistry. Hadar Feinberg et al., Mechanism for 
Recognition of an Unusual Mycobacterial Glycolipid by the Macrophage 
Receptor Mincle., J. Biol. Chem., 2013; 288: 28457–28465. © the 
American Society for Biochemistry and Molecular Biology. With 
permission. 
 
 
To explore the effect of the lipid on TDM binding to Mincle, a series of trehalose esters 
were prepared using enzymatic syntheses and binding studies revealed that acylation of 
the two 6-OH groups are tolerated.69 This confirms that these groups are positioned 
freely on the surface of the CRD. Moreover, acylation with 3- or 4- carbon chains 
results in significantly enhanced affinities for Mincle as observed by the 
K1(trehalose)/K1(acyltrehalose) values. It is also important to note that the surface of the 
Mincle CRD near the primary sugar binding site contains a hydrophobic channel which 
is positioned directly adjacent to the 6-OH group of the primary glucose residue. 
Modelling studies have suggested that this hydrophobic channel would accommodate at 
least 6 carbon atoms. Furthermore, as the 6-OH group of the secondary glucose residue 
is positioned away from the CRD’s surface, one of the two lipids on TDM was thought 
to be less important for Mincle-binding. 
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In the second Mincle crystallographic study, Furukawa et al. also report on the crystal 
structure of the Mincle-citric acid complex and illustrate that Mincle, unlike other C-
type lectins, possesses a unique shallow hydrophobic region located adjacent to the 
sugar binding sites.70 Moreover, Furukawa et al. investigated the effect of the acyl chain 
on Mincle binding and using surface plasmon resonance (SPR) and a series of trehalose 
glycolipids with a single acyl chain of different carbon lengths (C8, C10, C12), 
illustrated that the trehalose with a single C8 acyl chain bound to Mincle with much 
lower affinity than those of C10 and C12. This highlights the ability of the hydrophobic 
region to accommodate an acyl chain of at least ten carbon atoms.70 
 
 
1.4 Liposomes 
 
Although TDMs and TDEs have many interesting properties when administered alone, 
their incorporation into liposomes has also found many interesting applications. 
TDM/TDE liposomes have been used as vaccine adjuvants,52,71-74 and to enhance the 
anti-cancer effect of the glycolipid component. It is important to note, however, that the 
use of TDM/TDE liposomes as drug delivery vehicles (i.e. to encapsulate drugs) has not 
been previously explored. Before trehalose glycolipid liposomes are discussed in more 
detail, a short review on liposome synthesis and properties will first be given.  
 
 
1.4.1 Overview 
 
Liposomes were first prepared by Watkins and co-workers in 1965.75 Liposomes 
resemble cell membranes in structure and composition and are typically made from 
phospholipids, which are considered to be non-toxic and non-immunogenic. Liposomes 
consist of one or more concentric lipid bilayers that enclose an internal aqueous 
volume76 and are classified into three categories on the basis of their size and lamellarity 
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(number of bilayers): small unilamellar vesicles (SUVs) are between 0.02-0.05 µm, 
large unilamellar vesicles (LUVs) are greater than 0.6 µm, and multilamellar vesicles 
(MLVs) range from 0.1-6 µm.77,78  
 
The ability to encapsulate or bind a variety of drugs into or onto the membrane  of 
liposomes makes them attractive candidates as drug delivery vehicles and their clinical 
applications include use as chemotherapies for cancer and fungal infections, and 
vehicles for vaccination and gene therapy.76 The versatile nature of liposomes means 
that many different components can be added or removed and their properties can thus 
be tailored to the respective application. For example, drugs can be incorporated in 
liposomes in the hydrophobic hydrocarbon core, on the polar surface, or in the internal 
aqueous space.76  
 
 
1.4.2 Synthesis of Liposomes 
 
The method used to prepare liposomes is important because it determines the type of 
liposome formed. The general preparation of liposomes involves four stages ' removal 
of the organic solvent to form the lipid, dispersion of the lipid into aqueous media, 
purification of the resultant liposome, and then characterisation. Generally, MLV are 
prepared using the method reported by Watkins and co-workers,75 whereby a lipid 
mixture in organic solvents was allowed to deposit upon the walls of a round bottom 
flask by rotary evaporation under reduced pressure. The thin lipid film is then dispersed 
in aqueous buffer at a temperature above the transition temperature (Tc) of the lipid to 
disperse large lipid aggregates. On the other hand, SUVs are prepared by injecting an 
aqueous suspension of lipids under high pressure through a “French press” and the 
liposomes can be subsequently fractionated by size, by centrifugation, or molecular 
sieve chromatography.79 LUVs are prepared via ether injection, in which an ether 
solution of lipid is injected into an aqueous medium.79 Several modifications have been 
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made to the general methods described above so as to tailor the exact properties of the 
liposomes. 
 
 
1.4.3 Liposomes in Immunology 
 
Liposomes generally used in immunological studies are multilamellar in structure 
because of the ease of encapsulation of proteins and the variety of lipid compositions 
that can be used.80 Here, a long hydration and gentle shaking rather than a faster and 
more vigorous preparation can achieve a higher percentage of encapsulation per mole of 
lipid.80 In addition, egg lecithin or phosphatidylcholine (PC) are often considered to be 
important materials of liposomes used for adjuvant activity because both substances are 
biodegradable and non-toxic when administered as liposomes.80,81 More importantly, the 
advantage of phosphatidylcholine liposomes as adjuvants is that PC is a very poor 
antigen, as compared to other lipids such as phosphatidyl inositol, phosphatidyl glycerol, 
and phosphatidic acid.80 
 
There are two major interactions between liposomes and cells that must be considered in 
liposome applications for drug delivery.82 The most important interaction is lipid 
exchange and is a long-range interaction that involves the exchange of liposomal lipids 
for the lipids in the cell membrane of various cells. The second major interaction is 
adsorption. Adsorption occurs when the attractive forces (including electrostatic, van der 
Waals, hydrophobic insertions and hydrogen bonding) exceed the repulsive forces 
(electrostatic, steric, hydration).82 These interactions depend on the surface 
characteristics of the liposomes, such as charge and polarity. 
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1.4.4 Liposomes in Drug Delivery 
 
“Conventional” liposomes are liposomes composed of neutral and/or negatively charged 
lipids and cholesterol. Some of these conventional liposome formulations have reached 
the market, or are now entering clinical trials. For example, Ambisome( is a liposome 
formulation that encapsulates the antifungal amphotericin B drug, Myocet( 
encapsulates the anticancer agent doxorubin, and Daunoxome( has the drug 
daunorubicin incorporated into the liposome.83 The advantage of incorporating drugs 
into liposomes includes the ability to target specific cells, tissues or organs and enable 
the delivery of higher drug doses.84 Additionally, as the drugs are encapsulated in 
liposomes, they are expected to be transported without rapid degradation and with 
minimum side effects to the recipients.84  
 
Another type of liposome is the long-circulating liposome, which is based on the 
concept that steric stabilisation of the liposome increases its longevity in circulation. 
Here, a hydrophilic polymer or glycolipid, such as polyethylene glycol (PEG), which 
possess a flexible chain, can occupy the space immediately adjacent to the liposome 
surface (“periliposomal layer”) to exclude other macromolecules from this space.83 As a 
consequence, access and binding of blood plasma opsonins to the liposomal surface is 
hindered, thereby inhibiting interactions between M$s and the liposome,83 which is the 
main means by which liposomes are removed from circulation. Polyethylene glycols are 
also known to increase drug stability and solubility and lower toxicity, and when placed 
on the liposomal surface they prevent vesicle aggregation, thus improving the stability 
of formulations.83 PEG incorporation is achieved by anchoring the polymer in the 
liposomal membrane using a cross-linked lipid [i.e. PEG-
distearoylphosphatidylethanolamine (DSPE)].83 The successful application of Stealth 
liposomes is highlighted by the FDA approval of DOXIL( (Stealth liposomal 
doxorubicin HCl) for the treatment of Kaposi’s sarcoma in 1995.85 
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1.4.5 TDM/TDE Liposomes 
 
There have been several studies where TDM or TDB have been incorporated into 
liposomes. In early work, Nolibe et al. administered TDM-liposomes suspended in 
saline to Wister AG rats by the intratracheal (i.t.) route and monitored the activation of 
alveolar M$s as well as the activation of NK (natural killer) cells of the lung.52 Their 
results showed that TDM-liposomes administered via i.t. induced a transient 
inflammatory effect, such that the activated M$s had cytostatic activity against P77 
fibrohistiocytoma three days after administration. However, the NK activity of 
lymphocytes of the lung did not increase, which suggests that M$s may be the main 
effector cells responding to TDM. In addition, Nolibe et al. found that repeated i.t. TDM 
adminstration protected rats against the development of colonies arising from 
intravenously (i.v.) injected tumor cells. More recently in 2013, Carlétti et al. 
investigated the immune protection of an alanine proline antigen (Apa)-TDM-DNA 
vaccine against intratracheal M. tuberculosis challenge.71 Here, BALB/c mice were 
primed with BCG and a single dose of plasmid carrying Apa and TDM adjuvant co-
encapsulated in liposomes for a prime-boost strategy. Evaluation at 30 and 70 days post 
challenge showed that this prime-boost strategy resulted in a significant reduction in the 
bacterial load in the lungs and thus, the strategy holds much promise for the prevention 
of tuberculosis. 
 
The structurally related TDB has also been used in liposomal formulations. Kamath et 
al. and Gram et al. both investigated the liposome-based adjuvant CAF01 (also referred 
to as DDA-TDB or Lipovac) in mouse models.72,73 The CAF01 adjuvant is based on 
cationic liposomes formed by the quarternary ammonium lipid N,N!-dimethyl-N,N!-
dioctadecylammonium (DDA) and TDB, and when combined with the TB antigen Ag-
85B-ESAT-6, was used in Phase I clinical trials as a TB vaccine.74 Kamath et al. found 
that following adult or neonatal murine immunisation with Ag85B-ESAT-6 (5 !g) 
formulated in CAF01, the post-challenge bacterial growth of M. bovis BCG was reduced 
when compared to that observed using Ag85B-ESAT-6 formulated in aluminium 
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hydroxide (the control).72 Gram et al. also found that the CAF01 adjuvant induced a 
CD8+ T cell immune response against HIV-1 proteins in HLA-A*0201 transgenic mice 
that is comparable to that of incomplete Freund’s adjuvant.73 As CAF01 liposomes are a 
heterogeneous population with a mean vesicle size of 500 nm, Henriksen-Lacey et al. 
investigated whether various sized CAF01 liposomes in combination with Ag-85B-
ESAT-6 exhibited altered pharmacokinetics, cellular uptake and activation in vitro.74 
Their study showed that while there were no differences in the vaccine draining profile 
from the injection site, there were, however, significant changes in the movement of 
liposomes from the lymph node. Different size CAF01 liposomes showed a size-
dependent movement, where at both 6 h and 24 h post-injection, significantly higher 
levels of large (~ 1.5 µm) compared to small (~ 200 nm) DDA:TDB liposomes were 
detected in the popliteal lymph node. Milicic et al. further explored the effect of size of 
the DAA:TDB liposomes and determined that cationic DDA:TDB liposomes of the 
same chemical composition but different size and lamellarity differed in their ability to 
induce cellular immune responses.86 Small unilamellar liposomes of approximately 600 
nm in diameter when combined with Ovalbumin (OVA) protein were able to induce a 
higher cellular adaptive immune response than multilamellar vesicles with a two-fold 
larger diameter. This finding was unexpected as a smaller amount of OVA protein is 
incorporated in SUVs compared to MLVs (85% versus 95% of total dose of OVA 
protein). Thus, it is possible that a difference in the endocytic pathways involved in the 
internalisation of the two types of liposomes affects antigen presentation, and hence, the 
ensuing immune response. 
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1.5 Macrophages in disease 
 
M$s are innate immune cells and are one of the most versatile cells in the body. They 
play a critical role in innate immunity, inflammation and repair,87,88 and are the first line 
of defence against invading pathogens.89 To distinguish between infectious agents and 
self, a number of M$ phagocytic receptors have evolved, including the mannose 
receptor, which is involved in the recognition of PAMPs on pathogens.90 M$ are 
derived from hematopoietic cells that develop into monocytes in blood and which, upon 
entering tissues, differentiate into M$s.89 M$ are found in essentially all tissue, 
including the lungs, liver, brain, bone and skin, and depending on the tissue 
environment, are capable of different physiological functions.91 As discussed previously, 
M$ express Mincle and thus can interact with TDM and TDE. 
 
M$ have the distinctive ability to be able to polarise to different phenotypes that express 
unique cell surface molecules and secrete discrete sets of cytokines and chemokines. 
The classically activated, or ‘M1’ phenotype, supports the pro-inflammatory Th-1 
response that is driven by cytokines such as IL-12 and IL-23, while the alternative ‘M2’ 
phenotype is supportive of anti-inflammatory processes driven by IL-10.91 The ability of 
M$ to change phenotype is known as M$ plasticity, which, in some instances, can lead 
to or enhance disease. For example, tumour-associated macrophages (TAMs) are found 
in large numbers in solid tumours,92,93 and exhibit the alternatively activated ‘M2’ 
phenotype associated with immunosuppression, promotion of tumour angiogenesis and 
metastasis. As M$s are thought to play a role in the pathogenesis of diseases, the 
specific targeting and destruction of M$s may be a strategy that could find application 
in the treatment of cancer,94 and tuberculosis, whereby in the latter case, M.tb is known 
to reside inside the M$ and not be destroyed.95 
 
Early methods of depletion of M$s were based on the administration of silica, 
carrageenan or by various other treatments,96 however, depletion was often incomplete 
and unwanted side effects on other non-phagocytic cells were a disadvantage. Thus, a 
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more sophisticated approach was developed based on a liposome medicated intracellular 
delivery of the M$ depleting drug bisphosphonate clodronate. This approach has proven 
to be effective in several tumour models,97,98 such as the murine F9 teratocarcinoma and 
the human A673 rhabdomyosarcoma mouse tumour models,99 and also in clinical trials 
for patients with breast cancer.100 As only a small fraction of drugs that are injected in 
soluble form into the body reach M$s,101 there has been much interest in developing 
carrier systems, such as liposomes and microspheres, that will allow for the specific 
targeting of M$. In this manner, liposomes are used as a Trojan horse to deliver 
clodronate to the M$.96 Liposome-mediated therapies work because the liposome is 
preferentially engulfed by the phagocytic M$, however, for the strategy to be effective, 
M$s must be activated in such a way that phagosome-lysosome fusion is induced and a 
high intracellular threshold of clodronate is reached.102 Thus, increasing the degree of 
M$ activation remains an important obstacle in the development of better M$ depletion 
therapies. It is envisioned that this can be achieved by incorporating trehalose 
glycolipids into liposomes, which is an area of TG-liposome research that hasn’t been 
explored. 
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1.6 Research aims 
 
The objective of this MSc thesis was to: 
a. Explore the immunomodulatory potential of trehalose glycolipids (TGs), in 
particular, whether TMEs will bind and activate M$s via Mincle. 
b. Explore the potential of liposomes containing TGs, specifically TDEs and TME, 
with the future objective of developing improved drug delivery systems. 
 
The aim to improve the synthesis of the TMEs to further explore the Mincle binding site 
and investigate the structural requirements for activation of M$s will be discussed in 
Chapter Two. To this end, the synthesis of TMEs was undertaken and the ability of 
these monoesters to activate M$ explored, and compared to the biological properties of 
their diester counterparts. 
 
In Chapter Three, the effects of non-functionalised (or empty) liposomes, as well as TG 
containing liposomes on M$ activation were determined (by way of establishing NO 
production by M$). TG-liposomes synthesised contained the most active TG. These 
experiments thus represent the first steps to determining whether the addition of TG into 
liposomes can lead to better M$ depletion strategies. 
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CHAPTER 2: 
 
SYNTHESIS AND BIOLOGICAL EVALUATION 
OF C26-TME 
 
 
2.1 Overview 
 
There is much interest in the synthesis of trehalose diesters (TDEs) and their derivatives 
due to their interesting biological properties. Previous work performed within our 
laboratory by Khan et al. led to the first report of how TDE lipid length affects the 
innate immune response of M$s.28 Results from this work indicated that longer lipids 
("C18) are required for the activation of M$s, whereas TDEs with shorter chain lipids 
are inactive.28 This observation is significant as it provides an insight into why M.tb, 
which expresses long chain TDEs, has the ability to trigger an innate immune response. 
The synthetic route developed by Khan et al. for the formation of TDEs also led to the 
formation of trehalose monoesters (TMEs) as a side product.  
 
In this chapter, I describe the synthesis of the C26 TDE, as well as exploration of 
methodology to allow for the efficient synthesis of TMEs. The TMEs were then tested 
to determine if they activate M$, and if M$ activation is dependent on Mincle. These 
results will provide valuable structure-activity relationship data.  
 
 
2.2 Synthesis of TDE  
 
The synthetic strategy developed by Khan et al. was used to prepare the required C26 
TDE for incorporation into liposomes.28 To this end, trehalose 24 was treated with N,O-
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bis(trimethylsilyl)acetamide (BSA) and catalytic tetra-butylammonium fluoride 
(TBAF), then with K2CO3 to generate diol 19 in a one-pot procedure whereby 24 was 
first per-silylated, and then the more labile primary silyl ethers removed during work up 
by the addition of K2CO3 (Scheme 4).  
 
The TMS-protected derivative 19 was then coupled to hexacosanoic acid under the 
mediation of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) and 4-
dimethylaminopyridine (DMAP) in CH2Cl2 to give diester 25 in 60% yield. The TMS 
groups were then readily removed following subjection of the diester 25 to Dowex-H+ 
resin to yield the target C26 TDE 26 in 70% yield. 
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Scheme 4. Synthesis of TDE 26 (C26-diester); Reagents and conditions: i) BSA, 
TBAF (cat.), DMF, RT, 30 min, then propan-2-ol, 0 °C, K2CO3, 2 h, 
85%; ii) hexacosanoic acid, EDCI, DMAP, 60%; iii) Dowex-H+, 
CH2Cl2/MeOH (1:1), RT, 30 min, 70%. 
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The mechanism for the BSA-mediated silylation reaction commences with attack by the 
fluoride anion in tetra-butylammonium fluoride (TBAF) on to the silyl atom in N,O-
bis(trimethylsilyl)acetamide (BSA) (I) to generate intermediate II (Scheme 5). Attack 
on this silyl group is preferred due to the formation of a stable intermediate II, whereby 
the negative charge on the oxygen is resonance stabilised to form intermediate III. The 
negatively charged nitrogen atom in III then deprotonates a proton from one of the 
hydroxyl groups in trehalose to give a negatively charged oxygen atom in IV, which 
then attacks a silyl group in another molecule of BSA (I) and results in the formation of 
a TMS ether (V) and regeneration of intermediate II. 
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Scheme 5. Reaction mechanism for BSA mediated silylation of trehalose.28 
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2.3 Synthesis of TME  
 
Although the formation of TDEs can be achieved as described above, the synthesis of 
very-long chain ("C20) TMEs is nonetheless challenging as it is difficult to optimise 
mono- versus di-esterification. The reactivity of long-chain lipids is hindered by their 
poor solubility in many organic solvents and there are only few published syntheses for 
the formation of TMEs. 
 
In the literature, several strategies for the synthesis of medium to long-chain TMEs have 
been documented,103-105 and these methods include both enzymatic and non-enzymatic 
strategies. Csuk et al. reported on a convenient, protecting group free route for the 
synthesis of 6-O-trehalose monoester derivatives from trehalose.103 Their procedure is 
based on the selective chemoenzymatic monoesterification of trehalose to give TMEs in 
a synthesis without protecting groups in good yield (Scheme 6).103 In a typical reaction, 
trehalose 24 is reacted with vinyl oleate 27 in the presence of Alcalase, a commercially 
available enzyme from Bacillus licheniformis, for 18 days to give 6-O-mono 
derivative 29 in 72% yield. Under these same conditions, reaction of 24 and 13-
methylmyristoyl ester 28 allowed for the formation of monoacylated derivative 30 in 
74% yield. 
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Scheme 6. Chemoenzymatic synthesis of mono-acylated trehalose derivatives 29 
and 30 by Csuk et al.103 
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Other groups who have used enzymatic reactions to prepare fatty acid esters of trehalose 
are Tsuzuki et al. and Woudenberg-van Oosterom et al.104,105 Tsuzuki et al. investigated 
the use of a modified Lipase P from Pseudomonas sp. as a catalyst for the 
interesterification between an alcohol and fatty acid. Their results showed that 6-O-
palmitoylsucrose, 6-O-palmitoyllactose, 6-O-palmitoylmaltose, and 6-O-
palmitoyltrehalose diesters were the dominant products and only minor amounts (< 
10%) of the monoester were observed.105 As the monoester was formed in such small 
amounts, this methodology is not suitable if TMEs are the target compounds. 
 
Woudenberg-van Oosterom et al. studied the acylation of several disaccharides, 
including lactose, sucrose and trehalose, among others, using ethyl butanoate and ethyl 
dodecanoate in the presence of catalyst Candida antarctica lipase in tert-butyl 
alcohol.104 This group observed that the relative reaction rates of the various 
disaccharides were directly related to their solubility and the ratio of diester to 
monoester was markedly dependent on the structure of the disaccharide. In general, the 
first product formed was the monoester, derived from acylation of one of the primary 
alcohol groups. At greater substrate conversion rates, more diester product was 
observed, though the ratio of mono:di-ester product was dependent on the disaccharide 
structure. Interestingly, they noted the reaction of maltose with ethyl dodecanoate 
afforded only monoester, 6'-monododecanoate at a conversion of 17% after 24 hours, 
which increased to 34% after 48 hours. In contrast, trehalose afforded a 66% conversion 
to an equimolar mixture of mono- and diesters in 24 hours and a 86% conversion after 
48 hours, while the amount of monoester did not increase.104 On the other hand, lactose 
reacted at a very slow rate, with 2% conversion under the same reaction conditions.104 
Woudenberg-van Oosterom et al. suggested that carbohydrate solubility governs the rate 
of reaction, and that solubility is determined by the crystal lattice energy and by its 
solvation energy. As the melting point (MP) is a rough measure for the crystal lattice 
energy, the varying rates of conversion can be explained by the fact that trehalose has a 
MP of 98 °C, while lactose has a MP of 204 °C. 
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The Friess and Grindley groups have explored non-enzymatic methodology for the 
synthesis of TMEs. The Friess group describe the design and synthesis of trehalose fatty 
acid monoesters in four steps to produce high purity products.106 Their method begins 
with the silyl protection of !,!"-trehalose using the silylating agents trimethylsilyl 
chloride and hexamethyldisilazane in anhydrous pyridine, followed by selective 
deprotection at the 6- and 6"- positions using methanolic potassium carbonate in a 
manner similar to that previously described for the synthesis of the TDEs. 
Monoacylation of the symmetrical diol was then achieved using Steglich esterification 
conditions107 with palmitic acid, lauric acid or capric acid. The desired monoesters were 
obtained in high yields of 72 ' 78% following removal of the remaining six silyl 
protecting groups.106 In contrast, Grindley’s group published a protecting-group-free 
synthesis of 6-monoesters and 6,6&-diesters of trehalose using a primary-selective 
acylation procedure.108 They showed that reaction of trehalose with one equivalent of a 
fatty acid in pyridine promoted by one equivalent of the uronium-based coupling agent 
2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) at 
room temperature afforded the hexanoic, palmitic or oleic monoester in good yield (65 ' 
69%), along with a small amount of diester product.109 
 
The synthetic route towards the generation of very-long chain TMEs (" 22 carbons), 
however, is less widely documented and has only been reported a few times for the 
preparation of trehalose monocorynomycolates (TMCMs)110-112 and the synthesis of 
trehalose monomycolate en route to TDMs (as shown in Scheme 3).46 The remarkable 
differences between long (13 ' 21 carbons) and very long-long chain fatty acids is 
reactivity, which is attributed to differences in solubility and conformation.  
 
Accordingly, I explored the use of TMS-protected trehalose en route to the preparation 
of very-long chain lipophilic TMEs ("C22). To this end, the monoester, C26 TME 32, 
was synthesised using a similar three-step synthetic strategy to that described for the 
synthesis of the C26 TDE. Here, !,!&-trehalose (24) was again treated with BSA, 
catalytic TBAF and K2CO3 to generate TMS-protected diol 19 (Scheme 7). 
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Monoesterification of diol 19 with hexacosanoic (C26) acid to give monoester 31 was 
then investigated to optimise the reaction conditions. A number of conditions were 
employed with the objective of increasing the ratio of monoester 31 compared to the 
undesired C26 diester 25 or starting material 19.  
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Scheme 7. Synthesis of TME 32 (C26-monoester); Reagents and Conditions: i) 
BSA, TBAF (cat.), DMF, RT, 30 min, then propan-2-ol, 0 °C, K2CO3, 2 
h, 85%; ii) hexacosanoic acid, EDCI, DMAP; iii) Dowex-H+, 
CH2Cl2/MeOH (1:1), RT, 30 min, 97%. 
 
 
Previously, higher reaction temperatures (70 °C) were used for the synthesis of trehalose 
diesters,28 however, in an attempt to favour formation of monoester 31 the reaction was 
first performed at room temperature using different equivalents of acid (entries 1-2, 
Table 1). In both instances, the reactions were slow and mainly starting material was 
isolated with monoester 31 being formed in very poor (< 8%) yield. Here, it should also 
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be noted that 1H NMR could not be used to distinguish the ratio of products to starting 
material due to overlapping signals in the spectra and thus, the C26 TME and C26 TDE 
needed to be separated by column chromatography and the yield and ratio of the 
monoester to diester is based on isolated material. 
 
Table 1. Optimisation of synthesis of mono-ester 31. 
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Entry Temp/Time Acid (equiv.) DMAP EDCI Ratioa 
31:25 
Yield 31 (%)a 
1 RT, 7 d 1.5 0.1 1.8 31 only 5% 
2 RT, 7 d 1.8 0.1 2.0 31 only 8% 
3 70 °C, 6 d 4.0 0.1 5.0 1:3 20% 
4 70 °C, 4 d 1.3 0.1 1.8 33:20 33% 
5 70 °C, 7 d 1.8 0.4 2.0 19:1 38% 
6 70 °C, 7 d 1.8 0.2 4.0 7:4 35% 
7 70 °C, 7 d 1.8 4.4 4.0 9:3 45% 
aBased on isolated yield following purification by silica gel flash column chromatography 
 
 
As the reactions at room temperature were slow, the reaction was then warmed to 70 °C 
to aid with the solubility of the lipid. Here, excess hexacosanoic acid (4.0 equiv.), EDCI 
(5.0 equiv.) and catalytic DMAP at 70 °C gave diester 25 preferentially (entry 3), albeit 
in poor yield. TLC analysis of the reaction progress also illustrated that monoester 31 
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and diester 25 were formed simultaneously. Next, I set out to determine whether 
monoester 31 could be formed in preference to diester 25 by varying the equivalents of 
acid and the reaction time. To this end, 1.3 equivalents of acid with a reaction time of 4 
days led to an improvement in the yield of 31 (entry 4), and adding further acid (1.8 
equiv.), DMAP (0.4 equiv.) and increasing the reaction time to one week allowed for the 
synthesis of 31 in 38% yield (entry 5). Subsequent studies, whereby the amounts of 
DMAP and EDCI were varied (entries 6 and 7) allowed for an optimised 45% yield of 
monoester 31 to be obtained. During these later experiments, it was observed that an 
excess of DMAP, rather than the normal catalytic amount, proved crucial in improving 
the overall yield of monoester 31 (entry 7). To explain why excess DMAP was required 
to improve the reaction yield, it is presumed that the use of excess DMAP prevents the 
formation of N-hexacosanoyl urea,113 which is a well-known by-product of the Steglich 
esterification,107 particularly when using very long chain carboxylic acids that undergo 
slow esterification. To explain this mechanistically (Scheme 8), deprotonation of the 
carboxylic acid by EDCI and subsequent nucleophilic attack of the carboxylate at the 
carbodiimide occurs, but rather than attack by DMAP to give an activated ester 
(pathway B), which then reacts with alcohol 19 to give the desired monoester 31, an 
intramolecular reaction occurs (pathway A). Thus, intermolecular attack from the 
diimide nitrogen of the activated acid onto the carbonyl of the ester occurs to give the 
undesired N-hexacosanoyl urea side-product. Thus, excess DMAP was added to increase 
the likelihood of the formation of the DMAP activated ester.107 Finally, to complete the 
synthesis of TME 32, the TMS-groups in 31 were then deprotected with Dowex-H+ 
resin in 97% yield. 
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Scheme 8. Mechanism for the formation of N-hexacosanoyl urea side-product and 
desired ester product 31. 
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The 1H NMR spectra of TMS-protected TDE 25 and TMS-protected TME 31 are shown 
in Figures 4 and 5. In Figure 5, the significant dd resonances at 3.69 ppm and 3.71 ppm 
both have a coupling constant of 11.7 Hz, which are not seen in Figure 4. These 
resonances have been assigned to H-6a" and H-6b" in one glucose unit of trehalose, 
further supporting that 31 is only mono-acylated. Upadhyaya et al. have studied geminal 
proton-proton couplings in ketal ring systems and reported that exocyclic 
hydroxymethyl methylene protons have a coupling constant approaching 12 Hz,114 
which is consistent with the results reported for the TMS-protected TME 31. Similarly, 
for the C2-symmetrical diester 25, only one anomeric residue was observed at 4.92 ppm 
(d, J1,2 = 2.9 Hz, 2H, H-1), while for the monoester there were two overlapping signals 
at 4.93 ppm (d, J1/1',2/2' = 3.5 Hz, 1H, H-1/1') and 4.92 ppm (d, J1'/1,2'/2 = 3.5 Hz, 1H, H-
1'/1), respectively. Full characterisation was determined using 2D NMR, and the details 
of peak assignment are provided in the experimental chapter (Chapter 5). 
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Figure 4. 1H NMR spectra of TMS-protected TDE 25 
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Figure 5. 1H NMR spectra of TMS-protected TME 31 
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2.4 Biological evaluation of TMEs 
 
Following the development of an optimised route for the synthesis of C26 TME 32, the 
next step was to determine whether these TGs were able to activate M$ via Mincle. 
Accordingly, the ability of these TGs to cause bone-marrow-derived macrophages 
(BMMs) to produce NO and the cytokine IL-6 was explored. The cellular mediator NO 
is produced by M$ upon stimulation by bacteria and other pathogens, while the pro-
inflammatory cytokine IL-6 is released in response to specific PAMPs.59,64 Thus, by 
measuring NO and IL-6 production, the activation state of M$s can be deduced. 
 
For the biological assessment of the TGs, I isolated and cultured the M$s for the in vitro 
testing, while Dr Ashna Khan performed the biological testing (i.e. NO and IL-6 
production of the M$s in response to the different trehalose glycolipids). As highlighted 
previously, the C26 TME 32 and C26 TDE 26 glycolipid used in the biological 
experiments were synthesised by myself, while the C22 TME and C22 TDE (TDB) 
glycolipids were synthesised by Dr Ashna Khan. 
 
Mature M$s are difficult to isolate from tissue. Accordingly, there are several ways in 
which M$s can be obtained.115 One way is to use an immortalised M$ myeloid cell line, 
such as the human monocytic cell line THP-1,116 however, in the context of my studies, 
there is no equivalent Mincle-/- cell line, that can be used to determine the effect of 
Mincle on liposome uptake. Another way to obtain M$s is through primary M$ culture, 
whereby cytokines are used to differentiate progenitor cells (monocytes) from the bone 
marrow into mature M$s in culture.117 The main advantage of this method is that a 
homogenous population of M$s in a quiescent state are generated, which are responsive 
to activation by a stimuli in vitro.115 Moreover, Mincle-/- BMMs from the corresponding 
Mincle-/- mouse can be generated. 
 
Accordingly, to perform the in vitro experiments discussed in this thesis, I needed to 
isolate and differentiate the BMMs. To this end, bone marrow was extracted from the 
  58 
legs of both wild-type (C57BL/6) and Mincle-/- mice, to obtain the monocytes, and the 
monocytes were then stimulated with the appropriate cytokines to generate M$s with 
the required phenotype (Figure 6). As trehalose glycolipids are found on the cell wall of 
M. tuberculosis, which is a pathogen that causes an inflammatory immune response, the 
cytokine granulocyte macrophage colony-stimulating factor (GM-CSF) was added to the 
monocytes so as to generate M$s with a ‘M1’ or ‘pro-inflammatory’ phenotype. Further 
details about the process for the generation of BMMs from bone marrow is provided in 
the experimental section (see Chapter 5). Once generated, the cells were then given to 
Dr Ashna Khan. A variety of biological assays were performed and a summary of these 
findings is presented in this thesis. The full details of the experiments performed within 
the context of the work have recently been published.118 
 
 
 
Figure 6. Schematic for Bone Marrow Isolation and BMM Differentiation. A) 
Sacrifice mice. Use dissection tools to expose the hind legs and remove 
muscle from the bones. B) Cut the bones at both ends and flush the bone 
marrow using a syringe and needle into a falcon tube. C) Count the bone 
marrow cells using a haemocytometer. D) Plate the cells and culture 
BMMs in vitro. For the purposes of my experiment, the BMMs were 
cultured using GM-CSF. 
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The ability of C26 TME 32 and C22 TME to activate M$, as evidenced by production 
of NO and IL-6 by BMMs after incubation with TGs (TDE or TME) was determined 
using the Griess assay.59 The Griess assay is the most widely accepted classical method 
for measuring NO production and allows for the quantitative determination of nitrite 
(NO2-) ions in various samples using a colourimetric approach. The assay was used by 
Dr Ashna Khan to determine NO production by BMMs in response to the individual 
TGs, and later by myself to investigate the ability of liposomes containing the C26-TDE 
to activate BMMs.  
 
The Griess reagent system consists of N-(1-naphthyl)ethylenediamine (33) and sulfanilic 
acid (34) (Scheme 9). Specifically, the Griess assay detects the amount of nitrite present 
in a biological sample, with the nitrite itself being formed by the spontaneous oxidation 
of NO to NO2- under physiological conditions.119 Thus, in the presence of the nitrite 
anion, sulfanilic acid (34) reacts to form the diazonium salt 35, which then reacts with 
amine (33) to yield the azo dye 36, which can then be detected colourimetrically at 548 
nm. 
 
NH(CH2)2NH2 HO3S N2
NO2
HO3S NH2
NH(CH2)2NH2NNHO3S
33 35
34
36  
 
Scheme 9. The chemistry of the Griess assay, that detects NO production by cells.  
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As Mincle expression is strongly induced by pro-inflammatory stimuli, including 
lipopolysaccharide (LPS) and interferon-gamma (IFN-#), the ability of C26 TME 32 and 
C22 TME to activate C57BL/6 BBMs primed with IFN-# was first explored (Figure 7). 
IFN-#-primed BMMs were treated with 20 µg/mL'1 of C26 TME 32 or C22 TME, and 
at different time points (24 h, 48 h, 72 h and 96 h) the supernatant was collected and 
then analysed for NO. As illustrated, Figure 7 A shows that NO production by the 
BMMs in response to 20 µg/mL'1 of C22 (TME) and C26 TME 32 increased over a 96 h 
time period, although at a slower rate compared to TDB and LPS, both of which were 
used as positive controls. At 24 h, the C22 TME, C26 TME 32 and TDB, all induced 
similar levels of NO, however, after 96 h, the levels of NO were lower for C22 TME 
and C26 TME 32 (with 32 < C22 TME). The effect of glycolipid concentration on NO 
production was also investigated, as illustrated in Figure 7 B. Here, BMMs were 
incubated with 20 or 40 µg/mL of the trehalose glycolipids and at 96 h, modest increases 
in NO were observed with increased glycolipid concentration for both monoesters 32 
and C22 TME and for TBD (C22 TDE). These results show that TMEs are able to 
activate M$s and provides the first evidence for this phenomenon.118 
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Figure 7. Production of NO by TDB/TME-treated BMMs.A) BMMs were primed 
  with IFN-# (10 ng/mL) and stimulated with C26 TME 32 or C22 TME 
  (20 µg/mL), with TDB (20 µg/mL) or with LPS (100 ng/mL'1). At 24, 
  48, 72 and 96 h the supernatants were analysed for NO accumulation. B) 
  BMMs were treated with C26 TME 32 or C22 TME (20 µg/mL'1 or 40 
  µg/mL'1), with TDB, (20 µg/mL'1 or 40 µg/mL'1) or with LPS (100 
  ng/mL'1), and NO production was determined at 96 h. For both graphs, 
  the means and SDs of triplicate samples from representative experiments 
  performed in duplicate are shown.  
 
 
Having established that C26 TME 32 and C22 TME activate BMMs with priming, 
investigations into whether TMEs were able to activate M$s in the absence of priming 
were then conducted. Lang and co-workers previously demonstrated that TDB led to the 
induction of NO by BMMs, although at a lower level than when BMMs were primed by 
IFN-#.59 Thus, the abilities of C22 TME and C26 TME 32 to activate Mincle-/- BMMs 
without IFN-# priming were investigated, with use of LPS and IFN-# as positive 
controls and media alone as a negative control. From the studies performed in our group, 
however, it was determined that in the absence of IFN-# priming there was negligible 
A.       B. 
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NO production by the BMMs in response to either the mono- or di- esters over the 96 h 
time course (Figure 8 A).118 This result was surprising because Lang and co-workers had 
previously observed NO production by TDB,59 however, differences in the ability of 
TDB to activate M$s have been noted previously.120 The mono- and diesters, however, 
both led to the production of IL-6 by BMMs (Figure 8 B), thereby demonstrating that 
M$s can be activated without the need for priming. This is important as it demonstrates 
how the TGs in liposomes can be used to target M$s. If priming were needed, then it 
may mean that additional ‘priming’ agents (e.g. IFN-# or LPS) may need to be added to 
the liposome before performing any in vivo studies. Finally, it should also be noted that 
the TMEs were also able to active BMMs in a Mincle-dependent manner, (Figure 8 
B).118  
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A.       B. 
 
Figure 8. BMM activation without priming by IFN-#. A) NO, and B) IL-6 
production by TDE/TME-treated BMMs derived from Mincle-/-,  
TLR2/4-/- and C57BL/6. BMMs were primed with IFN-# (10 ng/mL'1) 
and stimulated with TMEs 32 or C22 TME, TDB, TDE 26 at 40 
µg/mL'1, or with LPS or PamCys at 10 ng/mL'1, and NO or IL-6 were 
measured after 72 h. For both graphs the means and SDs of triplicate 
samples from representative experiments performed in duplicate are 
shown. 
 
 
In experiments using Mincle-/- mice (in the presence of priming), neither NO 
production118 or IL-6 production (Figure 8 B) was observed for either the monoesters 32 
and C22 TME, or the diesters 26 or TDB (positive control), yet activity was observed 
when using the wild-type (C57BL/6) or TLR2/4-/- mice. Taken as a whole, these 
findings support the recent crystallographic evidence provided by Feinberg et al. and 
Furukawa et al.,69,70 which suggests that there is one major binding groove for a 
trehalose glycolipid ligand. The studies, however, also show in a functional assay that 
TMEs can activate M$s. Thus, it has been demonstrated that there is the potential to use 
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TMEs in the generation of liposomes as the TMEs appear to have similar biological 
activity to their diester counterparts. For the purposes of my research, however, I 
continued on with the synthesis and study of liposomes containing the C26 TDE to 
determine the experimental conditions, (e.g. liposome formulation, loading and 
glycolipid concentration), that are best suited for studying TG-liposome uptake by M$s. 
 
 
2.5 Conclusion 
 
In conclusion, the C26 trehalose monoester 32 containing a single acyl chain, was 
synthesised in good overall yield and shown to activate BMMs without the need for 
priming. This is the first time that a TME has been found to activate M$s, and by 
demonstrating that only one ester functionality is required, a new subclass of Mincle-
binding ligands has been discovered. These studies provide important background for 
the rational design of other Mincle agonists and indicate that liposomes containing 
TMEs may provide another avenue by which to better target M$s. 
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CHAPTER 3: 
 
FORMATION AND BIOLOGICAL EVALUATION 
OF TG-INCORPORATED LIPOSOMES 
 
 
3.1 Overview 
 
Having successfully synthesised the C26 TDE and TME, the next objective of this 
research project was to prepare liposomes containing these trehalose glycolipids and to 
determine whether the presence of the glycolipids influences the activation of M$. To 
this end, liposomes containing the C26 TDE at varying concentrations, as well was 
liposomes without the trehalose glycolipids (as a control), needed to be prepared.  
 
While there has been much research on the synthesis of liposomes as drug delivery 
vehicles, the exact liposome characteristics for optimal uptake by M(s depends on 
multiple factors including the phospholipids charge.97 Although, it is generally 
recognised that negatively charged lipids [e.g. phosphatidylserine (PS) and 
phosphatidylglycerol (PG)] are preferentially recognised by M(s,101 
phosphatidylcholine (PC) was selected for its neutral charge. Neutrally charged 
liposomes were desirable in this research, as it would allow the effect of TDE on 
phagocytosis by M(s to be better studied. Accordingly, the liposomes were prepared 
using PC, 69%, Cholesterol 30%, and the C26 TDE, with the ratio of PC:Cholestrol 
added being approximately 3:1, and with different amounts of the C26 TDE being added 
to the solution. Typically, concentrations of other cell targeting ligands [e.g. the single 
mannose head group ligand, monomannose-dipalmitoylphosphatidylethanolamine (8-
[carboxy-2-(1,2-dihexadecanoyl-sn-glycero-3-sodio-phospho)ethanolamido]octyl !-D-
mannopyranoside) or branched tri-mannose head group ligand, trimannose-
dipalmitoylphosphatidylethanolamine (8-[carboxy-2-(1,2-dihexadecanoyl-sn-glycero-3-
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sodio-phospho)ethanolamido]octyl (!-D-mannopyranosyl)-(1%3)-[(!-D-
mannopyranosyl)-(1%6)]-!-D-mannopyranoside] are added at loadings of 0 ' 20% of 
the total lipid weight,121 and thus, the initial amount of TDE to be incorporated was from 
4 ' 16% of the total lipid weight of the liposome. The molecular (lipid) weight for an 
empty liposome (i.e. the number of moles of phosphatidylcholine and cholesterol) was 
calculated, and loading at 4%, 8% and 16% of TDE was determined by calculation of 
these respective percentages from this total lipid weight (See Chapter 5 for 
representative calculations). Specifically, the work in this MSc thesis focused on the 
synthesis of ‘empty’ liposomes (i.e. liposomes without M$s depleting drugs or 
fluorescent material inside the liposome), with the results from these studies informing 
future work for the formulation of liposomes containing cargo and/or fluorescent dyes. 
 
 
3.2 Preparation of Liposomes 
 
To prepare the required liposomes, the dried-lipid film hydration method, as previously 
described by Van Rooijen et al.96 was used. The detailed protocol is provided in the 
experimental section and is briefly outlined here. Accordingly, PC, cholesterol and the 
C26 TDE were dissolved in a minimum volume of chloroform in a glass round-bottom 
flask and the chloroform was slowly removed under reduced pressure using a rotary 
evaporator so as to deposit a thin lipid film on the wall of the flask. Next, PBS (pH 7.4) 
was added to give a target TDE lipid concentration of 60 µM, and the resulting emulsion 
was dispersed by gentle rotation for 1 hour on the rotatory evaporator, followed by brief 
sonication (3 min), and resting for 2 hours at room temperature. Before use in in vitro 
assays, the liposome suspension was homogenised by gentle shaking before adding to 
cultures to achieve a homogeneous distribution of the liposomes in suspension. 
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3.3 Characterisation of Liposomes: Percentage of C26 TDE 
incorporated into liposomes 
 
The percentage of TDE incorporated into liposomes was examined using the phenol-
sulfuric acid method to analyse carbohydrate content.122 Although there are many 
colourimetric methods to analyse carbohydrate content, most use phenol and sulfuric 
acid and mainly differ in the concentration of reagents used. The phenol-sulfuric acid 
method is easy and reliably measures the neutral sugar content in oligosaccharides, 
proteoglycans, glycoproteins, and glycolipids.123  
 
The phenol-sulfuric acid assay works via the acid catalysed hydrolysis of glycosidic 
linkages followed by the reaction of phenol at the reducing terminus to give an adduct 
that can be detected colourimetrically. As illustrated (Scheme 10), reaction of the 
oligosaccharide (I) with H2SO4 gives lactol (II), which subsequently undergoes 
nucleophilic attack by phenol (III) at the anomeric centre to give the alcohol (IV). This 
adduct then undergoes an E1cB reaction to yield the coloured adduct (V), which is 
detectable at 490 nm.  
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Scheme 10. The mechanism of the phenol-sulfuric acid colourimetric assay. 
 
 
Before the amount of C26 TDE in the liposomes was determined, a calibration curve for 
a sugar standard needed to be determined. In this MSc project, the calibration curve was 
derived using !,!"-trehalose as the standard using concentrations of 0.1 mg/mL to 0.5 
mg/mL (Figure 9), with the measurements being performed in triplicate and a 
representative one of three experiments shown. It was assumed that for !,!"-trehalose, 
each molecule of trehalose reacts to form two molecules of dye. As illustrated, there is 
some variability with the measurements, however, the larger errors are observed at 
higher concentrations (i.e. above the concentration anticipated for C26 TDE loading in 
the liposomes). Moreover, for the purposes of the forthcoming biological assessment, it 
is an indication of the amount of C26 TDE incorporated into liposomes is provided 
rather than an absolute value.  
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Figure 9. Standard curve of !,!"-trehalose in distilled water. For the graph, the 
means and SE of triplicate samples from representative experiments 
performed in duplicate are shown. 
 
 
Having determined the calibration curve using !,!"-trehalose, those liposomes 
containing the C26 TDE were then analysed for their glycolipid content. To this end, the 
liposomes were prepared as previously described96 and then were pelleted by 
centrifugation at 10,000 RPM for 10 min and the PBS was removed using a glass pipette 
without disrupting the pellet. The liposomes were then resuspended in distilled water to 
an anticipated concentration of 0.5 mg/mL of trehalose diester, and titrated down in 2-
fold dilutions in triplicate into a 96-well plate and sulfuric acid added to each sample, 
followed immediately by 5% phenol solution. The 96-well plate was then incubated for 
5 mins at room temperature before the absorbance was measured on a microtiter plate 
reader at 490 nm.123 The absorbance of the unknown liposome suspension at 490 nm 
was then compared to that of the standard curve to give a percentage of C26 TDE 
incorporation (see Experimental section for the procedure). Accordingly, it was 
determined that the amount of C26 TDE incorporated into the liposomes was less than 
the total amount of TDE added to the solution (Table 2). In the target 4% TDE mol. 
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weight doping, only 13% of TDE was incorporated to give an actual TDE mol. weight 
doping of 0.5%, while, in the target 8% and 16% TDE mol. weight doping, higher 
percentages (28% and 40%) of TDE was incorporated to give an actual TDE mol. 
weight doping of 2.3 and 6.3%, respectively. From herein on, the percentage of actual 
C26 TDE incorporation is displayed (i.e. when discussing the biological results). 
 
Table 2. Percentage of C26-TDE incorporated into liposome stock suspensions.  
 
Target  
TDE mol. weight 
doping (%) 
Actual  
TDE mol. weight 
doping (%) 
 Percentage of TDE 
incorporated into 
liposome (%) 
4.0 
8.0 
16.0 
0.5 
2.3 
6.3 
13 
28 
40 
 
 
3.4 Characterisation of Liposomes: Size and distribution 
 
The sizes of the liposomes were measured on the Zetasizer Nano ZS using dynamic light 
scattering (DLS). This technique measures the time-dependent fluctuations in the 
intensity of scattered light, which occur because the particles are undergoing Brownian 
motion.124 Size measurements were made on the neat liposome suspension and also in 
samples, which were diluted 1 in 4 with PBS. The results from this work revealed a 
heterogeneous mixture of liposomes with an average size of 98 ± 31 nm for the empty 
phosphatidylcholine liposomes and an average size of 133 ± 37 nm for the C26 TDE 
containing liposomes. 
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3.5 Ability of Liposomes to Activate Macrophages 
 
The overall objective of this research was to determine whether liposomes containing 
TGs are preferentially phagocytosed by M$s. In this MSc thesis, I will describe the 
effect of C26 TDE containing liposomes on M$ activation to determine which liposome 
characteristics lead to M$ activation. As activated M$s are typically more phagocytic, 
such a readout will provide an indirect measure of liposome uptake. To confirm the 
preferential uptake of liposomes containing TGs, however, the liposome experiments 
will need to be repeated using liposomes containing a fluorescent dye, with uptake being 
measured by flow cytometry. Flow cytometry experiments are more time consuming 
and costly, and thus were not initially used. 
 
To determine M$ activation, the ability of the M$s to produce NO was explored. As 
described in Chapter 2, NO is the radical responsible for the cytotoxic effects of M$s 
and is commonly produced by activated M$s.59 Once again, the NO production by M$s 
was determined using the Griess Assay,59 however for the liposome studies discussed in 
Chapter Three, I performed all biological experiments. 
 
 
3.5.1 Titration of Phosphatidylcholine Liposomes 
 
Initially, I wanted to determine whether the lipids phosphatidylcholine (PC) and 
cholesterol that make up the majority of the liposome had an effect on the activation of 
BBMs. Accordingly, the BBMs were cultured from wildtype (C57BL/6), as well as 
Mincle-/- mice as described in Chapter Two, and on day 10 were subjected to 
PC/Cholesterol liposomes with varying concentrations of PC. The supernatant was then 
collected at 24, 48 and 72 hour time points and NO was measured. The positive control 
in these experiments was lipopolysaccharide (LPS), a known activating agent for 
BMMs,125 while the negative control was PBS alone. 
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Thus, a titration experiment was performed and the concentration of PC was decreased 
from 800 µM to 6.25 µM in both C57BL/6 (Figure 10 A) and Mincle-/- BMMs (Figure 
10 B). The Mincle-/- mice were used to determine if there was any substantial difference 
in the phenotype of BMMs from the Mincle knock-out mice, as future studies include 
determining whether the Mincle receptor influences the uptake of trehalose containing 
glycolipids. My experiments demonstrated that the BMMs were activated in a 
concentration-dependent manner with a modest increase in NO production being 
observed with increasing concentration of PC in liposomes in both C57BL/6 and in 
Mincle-/- mice, for a liposome concentration with " 200 !M of PC. Initially it was 
surprising that the PC/cholesterol liposomes led to NO production by BMMs as these 
types of liposomes are generally considered to be biologically inert. Accordingly, a 
more thorough review of the literature was undertaken to determine whether others have 
observed a concentration dependence of PC on biological activity.  
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A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
 
 
 
 
Figure 10. Titration of PC/cholesterol liposomes in BMMs. A) NO production by 
empty liposome-treated BMMs derived from C57BL/6 mice, and B) 
Mincle-/- BMMs were primed with IFN-# (10 ng/ml'1) and stimulated 
with a suspension of PC/cholesterol liposomes alone at various 
concentrations of PC, or with LPS (10 ng/ml'1) or PBS only. At 24, 48 
and 72 h the supernatants were analysed for NO accumulation. For both 
graphs the means and SDs of triplicate samples from representative 
experiments performed in duplicate are shown. 
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Previously, Grando et al. conducted in vitro experiments investigating the effects of 
saturated and unsaturated fatty acid-rich PC on rat M$ activity.126 Here, LPS-stimulated 
(10 ng/mL'1) peritoneal M$s were incubated with linoleic acid-rich-PC (unsaturated 
PC) and distearoyl-PC (saturated PC) and NO production was measured. In these 
studies, it was revealed that peritoneal M$s treated with unsaturated PC at 32 µM and 
64 µM concentrations led to a decreased production of NO in a dose-dependent manner 
compared to the positive control (LPS) by 30.4% and 46.4%, respectively. However, 
saturated PC at those same concentrations did not affect NO production of LPS 
stimulated M$s.126 The authors then studied the effect of the nature of the fatty acid on 
M$ viability. Accordingly, M$s were incubated with various concentrations of saturated 
PC and unsaturated PC and cell viability was determined by the colourmetric MTT (3-
[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay.126 Saturated PC and 
unsaturated PC were added to the M$ culture at concentrations up to 256 !M for 24 h, 
and the absorbance was measured at 570 nm. The M$s cultured for 2 h at any of the PC 
concentrations tested preserved cell viability, however, M$s incubated for 24 h with 256 
!M of saturated PC suffered a significant decrease in cell viability.126 This result 
provides evidence of the cytotoxic effect of PC at higher concentrations. 
 
In light of the findings by Grando et al., the composition of the L-$-PC manufactured by 
Sigma Aldrich was investigated. The MSDS for this product (P 3556, CAS 8002-43-5) 
states that there is a fatty acid content of approximately 33% of palmitic (16:0), 13% 
stearic (18:0), 31% oleic (18:1) and 15% linoleic (18:2), with other fatty acids being 
observed in minor amounts. Thus, the PC used for these experiments had a 1:1 ratio of 
saturated PC to unsaturated PC. In the experiments that I performed, NO production was 
observed at PC concentrations " 200 !M, which may be due to the toxicity of the PC 
and cell death leading to NO production by M$s (with M$s engulfing dead cells leading 
to NO production, which is a known phenomenon). The difference between my work 
and Grando et al. was that they stimulated M$s with LPS, which led to the production 
of NO (as seen in my own experiment) and therefore, M$ death would lead to a drop in 
overall levels of NO. 
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However, as observed in my experiments (Figure 11), there also appears to be some 
non-specific cell death of the M$s after 48 h, as observed by an increase in NO 
production in the negative control. Moreover, the effect is more pronounced in the 
Mincle-/- BMMs. These experiments (Figure 10 A and 10 B) were repeated several times 
(> 3 independent experiments), and with samples at all time points taken in triplicate, 
and thus, the results presented are from representative experiments and are reproducible. 
Accordingly, it seems that the most reliable time point to take in this assay is 48 h, 
which leads to NO production by M$s without any associated non-specific cell death. 
Similar trends were also observed in titration experiments in wildtype and Mincle-/- 
BMMs using solutions with different concentrations of PC only (data not shown), 
however, titrations of cholesterol alone were not performed as the cholesterol was 
insoluble in PBS, the buffer used in the liposomal formulations. 
 
While no non-specific cell death was observed in the TME studies presented in Chapter 
2 at 72 h and even at 96 h, (with the negative controls showing no NO production at 
these time points), others have observed non-specific cell death of M$s post the 48 h 
time period. For example, when exploring the liposomal cholesterol delivery to dissect 
the innate immune arm of M$s during Leishmania infection,127 Ghosh et al. studied 
M$s that were uninfected (normal) or infected with L.donovani and then treated them 
with PC and cholesterol-containing liposomes, together with an Acyl-CoA:cholesterol 
acyltransferase (ACAT) inhibitor (at 20 !g/mL) in vitro. At 24 h, NO generation had 
reached a maximum, however after this time period, NO levels suddenly decreased in 
both the infected and non-infected M$s, which was due to cell death.127 In these studies, 
the negative controls were uninfected (normal) and infected M$s that was left untreated, 
and no NO production was observed for these controls over the 48 h time course. Thus, 
it appears that non-specific cell death of M$s when subjected to liposomes can occur 
after longer time periods, and indeed, in my own work, levels of NO tend to rise for 
liposomes with higher concentrations of PC from the 0 – 24 h time period, with levels of 
NO production plateauing from the 24 – 48 h time period, before showing a slight 
increase. Perhaps the difference between the two general types of experiments (i.e. 
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individual TGs verses liposome formulation) is due to the fact that the liposomes, as 
compared to the individual TGs, are more readily phagocytosed and thus, the immune 
response peaks earlier, with the later rise in NO production (post 48 h) being due to non-
specific cell death. 
 
Similarly, König et al. analysed the proliferative capacity of BMMs after treatment with 
PC and cholesterol liposomes at 72 h in vitro and observed some non-specific death of 
M$s in response to liposomes and media alone.128 In these studies, empty liposomes 
were found to significantly reduce BMM proliferation compared to the control (PBS) 
and cell cycle analysis showed that empty liposome treatment caused cell cycle arrest at 
the G1/S boundary.128 Additionally, BMM apoptosis was also investigated and the 
degree of apoptotic cells was higher with empty liposome treatment than with the PBS 
control (13% vs. 7%),128 however, it should also be stressed that there was some non-
specific death of M$s in PBS alone. Thus, taken as a whole, care needs to be taken 
when measuring M$ activation at the later time points as non-specific cell death can 
occur. The effectiveness/appropriateness of an assay can be assessed by analysing the 
negative control to check for the activation status of the M$s in the absence of any 
stimulatants, however, as non-specific cell death has been observed for empty 
(unfunctionalised) liposomes, then the most appropriate time point to consider appears 
to be 48 h. In the context of my empty liposome studies, it is also important to note that 
all liposomal formulations and PC solution alone were checked for LPS contamination 
by using endotoxin detection kits.1 In all instances, no endotoxin was observed. 
 
In summary, my results have highlighted that to explore NO production as a 
consequence of TG incorporation into liposomes, the amount of PC used should stay 
below 200 !M to preserved cell viability and NO should be measured at the circa 48 h 
time point to account for potential M$ activation due to non-specific cell death. 
However, it may still be useful to measure NO activation at the 72 h time point and then 
                                                
1All liposome suspensions were tested to be endotoxin-free at a sensitivity of 0.125 EU/mL with an 
endotoxin-kit (Pyrotell, Limulus amebocyte lysate) according to the manufacturer’s instructions. 
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assess the data for its relevance, especially if the negative control does not show non-
specific cell death. (i.e. no NO production is observed). 
 
 
3.5.2 Activity of C26-TDE containing Liposomes: TG and Liposome 
concentration 
 
From my previous analyses, it was determined that liposomes with a PC concentration 
of less than 200 !M did not lead to significant NO production by BMMs. Accordingly, 
in the subsequent liposome studies aimed at investigating how liposomes containing the 
C26 TDE affect the activation of BMMs, I used a 105 µM concentration of PC. In these 
C26 TDE liposome studies, as illustrated in Figure 11, both the amount of liposome 
material added to the M$ and the percentage loading of the C26-TDE in the liposome 
was explored. As mentioned previously, the percentage incorporation of TDE into the 
liposomes is the approximate amount of actual TDE incorporated, as determined by the 
phenol-sulfuric acid test. 
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Figure 11. Cartoon representing the three different formulations of C26 TDE 
incorporated liposomes that were prepared. The lipsomes differed by 
both the concentration of the liposome solution and by the weight loading 
of the C26 TDE in the liposome with 6.3, 2.3 and 0.5% TDE loading. 
 
3.5.2.1 The effect of Liposome concentration on NO production by 
BMMs 
 
The first experiment performed involved exploring the total amount of C26 TDE that 
led to an increase in the production of NO by BMMs. To this end, C26 liposomes were 
formed by adding a 1.0 mg/mL solution of the C26 TDE when formulating the 
liposomes. While the target percentage of C26 TDE incorporation was 16%, the actual 
percentage was determined as 6.3% of C26 TDE incorporation (see section 3.3) into the 
liposome. The total amount of liposome added to an in vivo culture of BMMs was then 
serially diluted (Figure 12) and the amount of C26 TDE per suspension was determined 
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from the weight percentage loading per liposome stock suspension (full details of these 
calculations are provided in the experimental section). Thus, the amount of C26 TDE 
added per experiment (with a C26 TDE loading of 6.3 weight percent) could be 
determined from the target concentration of the liposomes at 60 µM, 30 µM and 15 µM. 
Thus, the amount of C26 TDE added into each well, for each of the three experiments 
correlated to 24 µM, 12 µM, and 6 µM, for the respective serial dilutions  
 
Figure 12. The liposomes containing a 6.3% weight loading of the C26 TDE for the 
initial 24 µM solution, which was then serially diluted to 12 µM and 6 
µM. 
 
 
To this end, BMMs cultured from C57BL/6 and Mincle-/- mice were thus subjected to 
C26 TDE incorporated liposomes in successive 2-fold serial dilutions and the Griess 
assay was conducted on supernatant collected after 24, 48 and 72 h. Again, LPS was 
used as a positive control, while media only was used as a negative control. As 
anticipated, there was a concentration dependence of M$ activation in relation to the 
amount of C26 TDE liposome added in the C57BL/6 mice (Figure 13), with there being 
negligible activation of BMMs when using liposome concentrations of less than 6 µM of 
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liposomes with a C26 TDE weight percent loading of 6.3%. Here, it is also important to 
note that a general decrease in NO production is observed after 24 h. This observation 
supports my earlier empty PC/cholesterol liposome studies, whereby the level of NO 
production reached a maximum at 24 h, after which NO levels drop between the 24 ) 
48 hr time period. A slight increase in NO observed at 72 h, again suggests that more 
non-specific cell death of M$s occurred with longer incubation times with liposomes, 
(Figure 13). 
 
 
 
Figure 13. Titration of C26 TDE liposomes (6.3 weight %) in C57BL/6 BMMs. NO 
production by C26 TDE liposome-treated BMMs derived from C57BL/6 
mice. BMMs were primed with IFN-# (10 ng/ml'1) and stimulated with a 
suspension of C26 TDE liposomes at various concentrations of C26 
TDE, or with LPS (10 ng/ml'1) or media only. At 24, 48 and 72 h, the 
supernatants were analysed for NO accumulation. For the graph, the 
means and SDs of triplicate samples from representative experiments 
performed in duplicate are shown. 
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In the case of the Mincle-/- BMMs (Figure 14), an unexpected dependence of M$ 
activation (NO production) with respect to liposome concentration was also observed. 
Due to the unexpected nature of these results, these experiments were performed three 
times, with all time points being recorded in triplicate, however, in all experiments, NO 
was produced by Mincle-/- BMMs in response to the liposomes. Again, there was a 
dependence of NO production by M$s in response to liposome concentrations, with 
negligible NO being produced at concentrations of less than 6 µM of 6.3 weight percent 
of C26 TDE. What is interesting to note, however, is that in the case of the Mincle-/-, NO 
production peaked at 24 h, with a plateau occurring at 48 h, and then with a subsequent 
increase in NO production at 72 hr, which is probably due to non-specific cell death.127 
Accordingly, when considered alongside the empty liposome data (Figure 10), the 
BMM Mincle-/- M$s appear to be a less robust cell line. 
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Figure 14 Titration of C26 TDE liposomes (6.3 weight %) in Mincle-/- BMMs. NO 
production by C26 TDE liposome-treated BMMs derived from Mincle-/- 
mice. BMMs were primed with IFN-# (10 ng/ml'1) and stimulated with a 
suspension of C26 TDE liposomes at various concentrations of C26 
TDE, or with LPS (10 ng/ml'1) or media only. At 24, 48 and 72 h, the 
supernatants were analysed for NO accumulation. For the graph, the 
means and SDs of triplicate samples from representative experiments 
performed in duplicate are shown. 
 
 
Thus, when considering the effect of liposome concentration on M$ activation, it is 
apparent that more NO is produced with increasing liposome concentration, and that a 
concentration of liposomes greater than 12 !M is required for significant activity. For 
the reproducibility of responses, it is also suggested that measurements are made at the 
48 h time point or earlier, especially for the Mincle-/- M$. Initially, the observation that 
Mincle-/- BMMs when treated with C26-TDE liposomes resulted in NO production was 
unexpected, as it has been previously shown by research in our group118 and in studies 
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by Lang and co-workers,59 that there is no NO production by Mincle-/- BMMs in 
response to the individual TGs. When the glycolipids are incorporated into liposomes, 
however, it may be possible that the process of M$ phagocytosis activates the BMMs to 
some extent and that is why NO production is observed by Mincle-/-, although it should 
be noted that empty liposomes (containing a 105 µM concentration of PC) do not lead to 
the production of NO (as discussed in section 3.5.1). Since the inception of this project, 
another receptor for TGs, namely the Macrophage C-type lectin, MCL, was identified 
and shown to have an influence on the immune response to TGs,63,129 and thus, it is also 
possible that MCL is involved in the phagocytosis of the TG-containing liposomes. 
 
While Mincle is still necessary to generate a robust immune response to TGs and its 
expression in M$ is induced by TGs, MCL is constitutively expressed in myeloid cells 
and the receptor has been shown to be an endocytic receptor.63 Studies involving the co-
transfection of non-myeloid cells with MCL, Mincle and FcR#, followed by 
immunoprecipitation, have provided evidence for a covalently linked heterodimer of 
MCL and Mincle that associated with FcR#, which suggests that Mincle acts as a bridge 
for the interaction between MCL and FcR#.130,131 Further, MCL was shown to be 
required to drive Mincle expression in a Clec4e–GFP fusion reporter mouse.63 
Moreover, recent work performed in our group has shown that while Mincle is 
important for the activation of BMMs, the uptake of polystyrene beads coated with TGs 
is greater than the uptake of non-TG-coated beads, however, the difference in uptake is 
not Mincle-dependent.132 Thus, in light of the results obtained in my experiments, it 
appears as if Mincle is not the only factor that influences the uptake of liposomes 
containing TGs. 
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3.5.2.2 Activity of C26-TDE liposomes compared to C26-TDE 
solutions 
 
As the previous experiment showed that C26 TDE liposomes at higher liposome 
concentration could activate BMMs, next I wanted to investigate how the uptake of C26 
TDE liposomes was influenced by different TG-doping levels (at target weight loading 
percentages of 4, 8 and 16% at 60 µM, but incorporation as determined by the phenol-
sulfuric acid assay found actual concentrations to be 24 µM, 17 µM, and 7.5 µM and 
how NO production by M$ was affected by the delivery mode of the C26 TDE (i.e. as 
an individual compound or in a liposome formulation). The types of liposomes tested 
are depicted in Figure 15. 
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Figure 15. The liposomes containing a weight loading of 6.3, 2.3 and 0.5% of C26 
TDE 
 
 
To this end, C26 TDE liposomes or C26 TDE solution (2% DMSO in PBS) were 
incubated with BMMs and on day 10, NO production was examined at 24, 48 and 72 h 
time points for the liposomes containing different amounts of C26 TDE (Figure 16). As 
observed, different TDE percentage loadings effect M$ activation to varying degrees 
when compared to the C26 TDE alone. Liposomes containing 6.3% C26 TDE show a 
much greater level of NO production compared to liposomes containing 2.3% TDE 
(seen by comparison of the bold blue line compared to the bold green line), however, 
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there is less of a difference between NO production by the 2.3% TG doped liposomes 
compared the 0.5% doped liposome. Thus, for an optimal immune response, a doping of 
at least 6.3% C26 TDE is required. It also appears that liposomal presentation of C26 
TDE leads to a similar level of M$ activation by the TG alone (compare the respective 
coloured bold and dotted lines). This is a significant finding as less C26 TDE is required 
to get the same effect, which suggests the addition of TG into the liposome does seem to 
have some synergistic effect  
 
Thus, in summary, the addition of TG to liposomes appears to increase the activation of 
M$ to a greater extent than the addition of either the liposomes or the TG alone. While, 
the measurement of NO production by M$s does not directly provide a measure of the 
phagocytic capacity of the M$, it does suggest that TG-containing liposomes enhance 
the phagocytic capacity of M$s. This hypothesis is further supported by the subsequent 
studies performed in our group using fluorescent TG-coated beads,132 however, from the 
data gathered to date, it appears as though any such preferential uptake of TG-containing 
liposomes is not mediated by Mincle. That said, further experiments involving the 
uptake and flow cytometry analysis of fluorescently labelled liposomes would be 
required to confirm whether the addition of TGs to liposomes does actually lead to a 
significant difference in the uptake of liposomes, as only indirect ways to assess this 
have been performed to date. 
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Figure 16. Activation of BMMs from C57BL/6 by C26-TDE liposomes and C26 
TDE solutions. BMMs were primed with IFN-# (10 ng/ml'1) and 
stimulated with a suspension of C26 TDE liposomes alone, C26 solution, 
or with LPS (10 ng/ml'1) or PBS only (100 !l). At 24, 48 and 72 h the 
supernatants were analysed for NO accumulation. For the graph the 
means and SDs of triplicate samples from representative experiments 
performed in duplicate are shown. 
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3.6  Conclusion 
 
In conclusion, PC/cholesterol liposomes were found to activate BMMs derived from 
C57BL/6 and Mincle-/- mice, as determined by the production of NO. The 
PC/Cholesterol liposomes were then titrated from 800 µM to 6.25 µM to reveal that 
liposomes containing less than 200 µM of PC did not lead to significant NO production 
by BMMs. A liposome formulation was then developed to contain 105 !M of PC, 
cholesterol, and C26 TDE loading at 0.5, 2.3 and 6.3 weight percentages, with the 
amount of C26 TDE incorporated into the liposomes being determined by the phenol-
sulfuric assay. The C26 TDE liposomes are able to activate both C57BL/6 and Mincle-/- 
BMMs, which suggests that Mincle is not essential for the activation of BMMs. 
Moreover, there is preferential activation of BMMs by TDE-liposomes at higher 
concentrations when compared to TDE solutions alone. Taken as a whole, the assay 
conditions and formulations of the liposomes required for M$ activation have been 
determined and provisional results have been obtained which suggest that the 
incorporation of TGs into liposomes does increase the activation of M$s (as compared 
to liposomes or TG alone). These are promising results towards the development of TG-
liposomes for M$s-depletion therapies for diseases such as cancer. 
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CHAPTER 4: 
 
CONCLUSIONS AND FUTURE PROSPECTS 
 
 
4.1  Conclusions 
 
The use of bacteria and bacterial components in the treatment of disease is widely 
documented and is an area of great interest. Accordingly, this thesis sought to explore 
how TMEs influence the activation of the innate immune response and whether TGs can 
be used to develop better liposomal drug delivery systems. 
 
In Chapter Two, the synthesis of the C26 TME was explored and an efficient synthetic 
route for access to these very long chain trehalose monoesters was optimised. As very 
long chain carboxylic acids have low reactivity, it was found that excess DMAP 
increased the likelihood of the formation of the activated ester, which then undergoes an 
intramolecular reaction with an alcohol to give the desired monoester product. It was 
proposed that excess DMAP reduces the possibility of intermolecular attack from the 
nitrogen of the activated acid onto the carbonyl of the ester, which would result in the 
undesired N-hexacosanoyl urea side-product. In the biological assessment of the TMEs, 
it was observed that these monoesters activate M$s in a manner similar to their diester 
counterparts, whereby the activity of the BMMs was dependent on Mincle. This result is 
significant as it is the first time that TMEs have been found to activate M$s and 
demonstrates that only one ester functionality is required for M$ activation.  
 
The synthesis of liposomes containing the C26 TDE was then explored in Chapter 
Three. Here, the phenol-sulfuric acid assay was used to determine the percentage of 
TDE incorporated into the liposomes and DLS was used to determine the size range and 
distribution of both the TG-liposomes and the non-functionalised (PC/cholesterol) 
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liposomes. Titration experiments were performed using the PC/cholesterol liposomes, 
whereby the concentration of PC was decreased from 800 µM to 6.25 µM in both 
C57BL/6 and Mincle-/- BMMs. PC was found to lead to NO production by M$s at 
higher concentrations (" 200 !M), which was thought to be due cell death. Thus, the 
liposomal formulations for the C26 TDE-containing liposomes were developed so that 
the solutions contained 105 !M of PC to preserve cell viability and thereby enable the 
effect of TG incorporation into the liposomes to be more effectively explored. The 
formulation of C26 TDE incorporated liposomes was explored with weight percentages 
of loading at 0.5, 2.3 and 6.3%. In this work, the C26 TDE incorporated liposomes were 
able to activate both the C57BL/6 and the Mincle-/- BMMs in a concentration-dependent 
manner. It was unusual that the TG-liposomes activated Mincle-/- BMMs, however, this 
may be due to the fact that the BMMs more readily phagocytose the liposomes, or it 
may be an effect of another more recently identified TG receptor, MCL. The results in 
this thesis, however, suggest that there is preferential activation of BMMs by TG-
liposomes compared to individual TGs in solution, though this is dependent on the 
percentage loading of the TG into the liposome. 
 
Thus, in summary, the research carried out for this thesis contributes towards an 
understanding of how TG structure influences M$ activation. Moreover, the work 
provides the ground work to suggest that TG-liposomes may be useful tools for more 
specific M$s-depletion strategies, particularly in diseases such as cancer where TAMs 
are known to lead to poor patient outcomes. 
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4.2  Future Prospects 
 
The aforementioned investigations into the biological properties of TGs and the 
activation of M$s represent significant steps towards the development of adjuvants and 
drug delivery systems. That said, further studies are required to better explore these 
respective research areas, particularly with regard to the TG-liposome drug delivery 
systems.  
 
In particular, Flow Cytometry analysis of the uptake of fluorescent liposomes by M$s is 
required so that a more direct measure of M$ phagocytosis (and hence, the uptake a 
potential drug inside the liposome) can be better explored. In such studies, a fluorescent 
dye could be encapsulated within the liposome itself or a fluorescent lipid could be used 
when synthesising the liposome. Herein, it should be noted that some time was 
expended on the synthesis of BODIPY (boron-dipyrromethene)-cholesterol in this 
Master’s Thesis, with the particular aim of formulating fluorescent C26-TDE liposomes 
whereby cholesterol contained a fluorescent reporter group.133 Complications, however, 
arose during the purification of this compound. While some of the desired dye was 
formed (as determined by 1H and 13C NMR, as well as 2D NMR data), there was 
insufficient time to optimise the synthetic strategy and silica-gel chromatography proved 
unsuitable for the separation of the BODIPY starting material from the desired product.  
Nonetheless, it is envisioned that this strategy could be optimised and that the 
fluorescent liposomes could then be used in experiments to provide information on 
liposome uptake and cell activation via the use of Flow Cytometry. Alternatively, 
another strategy could be explored whereby a dye, such as fluorescein or rhodamine, 
could be encapsulated inside the liposome so that the fluorescent liposomes could be 
generated in this manner.134 
 
Flow cytometry experiments with the fluorescent liposomes would then allow for more 
detailed information about the uptake of liposomes by M$s. For instance, BMMs 
incubated with fluorescent PC/cholesterol or fluorescent C26 TDE liposomes can be 
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analysed (at various time points) to see if C26 TDE liposomes are preferentially taken 
up by M$s by measuring Mean Fluorescence Intensity (MFI), as compared to the MFI 
of liposomes without the TGs. Additionally, the activation of M$s may also be 
investigated via the detection of specific cell surface markers on the M$s, such as CD80 
and CD86, which can be detected by co-staining with fluorescent antibodies and flow 
analysis. Moreover, in vivo experiments with fluorescent liposomes would allow for 
investigations into whether specific subtypes of M$s preferentially phagocytose the 
liposomes. Again, this can be determined by use of Flow Cytometry and the specific M$ 
sub-populations identified using range of cell surface markers. 
 
Another avenue of future work would be to investigate the effect of MCL on liposome 
uptake, particularly as MCL is an endocytic receptor. Such studies, however, would 
require access to MCL-/- mice, which are not currently widely available. It would 
nonetheless be interesting to ascertain whether MCL is responsible for the activation of 
M$s by the TG-liposomes. 
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CHAPTER 5: 
 
EXPERIMENTAL PROCEDURES 
 
 
General methods and materials for trehalose ester synthesis: Unless stated, all 
reactions were performed under N2. Prior to use, pyridine was dried and stored over 4 Å 
molecular sieves (4Å MS), CH2Cl2 was distilled from P2O5 and toluene was dried and 
stored under Na wire. D-(+)-Trehalose dihydrate (Sigma), anhydrous DMF (Acros), 
EDCI (Aldrich), DMAP (Merck), hexacosanoic acid (Acros), TBAF (Aldrich), N,O-
bis(trimethylsilyl)acetamide (Fluka), Dowex-H+ (Supelco), anhydrous Et2O (Biolab), 
EtOAc (Pancreac), petroleum ether 40 ) 60 (PE) (Pure Science), MeOH (Pancreac), 
isopropanol (Pure Science), CHCl3 (Pancreac), NaHCO3 (Pure Science), K2CO3 (Pure 
Science), MgSO4 (Pure Science) and NaCl (Pancreac) were used as received. All 
solvents were removed under reduced pressure. Reactions were monitored by TLC 
analysis on Macherey-Nagel silica gel coated plastic sheets (0.20 mm with fluorescent 
indicator UV254) via detection by UV absorption (short wave–254 nm; long wave–366 
nm) and by dipping in 10% H2SO4 in EtOH followed by charring at 150 °C. Column 
chromatography was performed using Pure Science silica gel (40-63 µm). AccuBOND 
II ODS-C18 (Agilent) was used for reverse chromatography. High resolution mass 
spectra were recorded on a Waters Q-TOF PremierTM Tandem Mass Spectrometer 
using positive electro-spray ionisation. Optical rotations were recorded on a Perkin-
Elmer 241 polarimeter or Autopol II (Rudolph Research Analytical) at 589 nm (sodium 
D-line). Infrared spectra were recorded as thin films using a Bruker Tensor 27 FTIR 
spectrometer equipped with an Attenuated Total Reflectance (ATR) sampling accessory 
and are reported in wave numbers (cm'1). Nuclear magnetic resonance spectra were 
recorded at 20 °C in C5D5N or CDCl3 using a Varian INOVA operating at 500 MHz. 
Chemical shifts are given in ppm ()). NMR peak assignments were made using COSY, 
HSQC and HMBC 2D experiments. 
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2,2!,3,3!,4,4!-Hexa-O-trimethylsilyl-","!-D-trehalose 
(19) Trehalose dihydrate 24 (1.33 g, 3.52 mmol) was 
coevaporated with anhydrous DMF (3*10 mL) and 
dissolved in DMF (5 mL). N,O-
bis(trimethylsilyl)acetamide (7.4 mL, 30.2 mmol) and 
TBAF (0.04 mL, 0.04 mmol) were added to this solution, and the mixture was stirred at 
RT for 1.5 h. The reaction was then quenched by the addition of isopropanol (1 mL), 
and the resulting solution was diluted with MeOH (80 mL) and cooled to 0 °C. A 
solution of K2CO3 (0.488 g) in MeOH (107 mL) was added, and the mixture was stirred 
at 0 °C for a further 2 h. The reaction mixture was then neutralised with AcOH (0.53 
mL) and concentrated in vacuo, and the residue was partitioned between Et2O and brine. 
The aqueous layer was extracted with Et2O (2*50 mL), and the combined organic layers 
were dried (MgSO4), filtered, and concentrated in vacuo. Purification by silica-gel 
column flash chromatography PE/EtOAc 4:1, v/v) gave diol 19 as a white solid (2.73 g, 
3.52 mmol) in 94% yield. Rf  = 0.28 (PE/EtOAc 3:1, v/v); 1H NMR (500 MHz, CDCl3): 
) 4.91 (d, J1,2 = 3.1 Hz, 2H, H-1), 3.90 (t, J2,3 = J3,4 = 9.0 Hz, 2H, H-3), 3.88–3.84 (m, 
2H, H-5), 3.72 (dd, J6a,6b = 11.8, J5,6a = 2.7 Hz, 2H, H-6a), 3.70, (dd, J6a,6b = 11.8, J5,6b = 
3.9 Hz, 2H, H-6b), 3.49 (t, J3,4 = J4,5 = 9.0 Hz, 2H, H-4), 3.42 (dd, J2,3 = 9.0, J1,2 = 3.1 
Hz, 2H, H-2), 0.17, 0.15, 0.13 ppm (3*s, 54H, CH3, TMS); All other spectroscopic data 
and analyses were repeated and matched those reported by Khan et al.28 
 
 
6,6!-Di-O-hexacosanoyl-2,2!,3,3!,4,4!-hexa-O-
trimethylsilyl-","!-D-trehalose (25) EDCI (0.73 g, 
4.69 mmol) and DMAP (0.026 g, 2.13 mmol) were 
added to a solution of diol 19 (1.102 g, 1.42 mmol) and 
hexacosanoic acid (37.9 mg, 0.096 mmol) in dry 
toluene (5 mL). The mixture was stirred at 70 °C until 
TLC showed the reaction to be complete (6 days). The 
resulting precipitate was removed by filtration and washed with EtOAc (2*50 mL); the 
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combined organic layers were washed with water (50 mL) and brine (40 mL), dried 
(MgSO4), filtered and concentrated in vacuo. The product was purified by silica-gel 
flash column chromatography (PE/EtOAc 50:1, v/v) to give TDE 25 as a white solid 
(2.16 g, 1.42 mmol, 85%). Rf = 0.84 (PE/EA, 5/1, v/v); 1H NMR (500 MHz, CDCl3) ) 
4.92 (d, J1,2 = 2.9 Hz, 2H, H-1), 4.28 (dd, J6a,6b = 11.7 Hz, J5,6a = 2.2 Hz, 2H, H-6a), 4.06 
(dd, J6a,6b = 11.7 Hz, J5,6b = 4.7 Hz, 2H, H-6b), 4.02–3.98 (m, 2H, H-5), 3.91 (t, J2,3 = 
J3,4 = 9.0 Hz, 2H, H-3), 3.48 (t, J3,4 = J4,5 = 9.0 Hz, 2H, H-4), 3.45 (dd, J2,3 = 9.0 Hz, J1,2 
= 2.9 Hz, 2H, H-2), 2.36 (dt, J8a,8b = 13.6 Hz, J8a,9 = 7.3 Hz, 2H, H-8a), 2.34 (dt, J8a,8b = 
13.6 Hz, J8b,9 = 7.0 Hz, 2H, H-8b), 1.64–1.60 (m, 4H, H-9), 1.34–1.18 (m, 88H, H-10–
H-31), 0.89 (t, J31,32 = 6.7 Hz, H-32), 0.16, 0.14, 0.137 ppm (3*s, 54H, CH3, TMS); All 
other spectroscopic data and analyses were repeated and matched those reported by 
Khan et al.28 
 
 
2,2!,3,3!,4,4!-Hexa-O-trimethylsilyl-6-hexacosanoyl-
6!-hydroxy-","!-D-trehalose (31) EDCI (0.20 mmol, 
2 equiv) and DMAP (0.44 mmol, 4.4 equiv) were 
added to a solution of 2,2&,3,3&,4,4&-hexa-O-
trimethylsilyl-$,$&-D-trehalose (19, 0.1 mmol, 1 equiv.) 
and hexacosanoic acid (0.18 mmol, 1.8 equiv) in dry 
toluene (5 mL). The reaction mixture was stirred at 70 °C for seven days. The resulting 
precipitate was removed by filtration, and the precipitate was washed thoroughly with 
EtOAc (2*50 mL). The combined organic layers were washed with water (50 mL) and 
brine (40 mL), dried (MgSO4), filtered and concentrated in vacuo. The product was 
purified by silica gel flash chromatography (elution with Pet.Ether/ EtOAc 20:1) to give 
TME 33 in 45% yield. Rf = 0.62 (PE/EA 5:1, v/v); 1H NMR (500 MHz, CDCl3): " 4.93 
(d, J1/1&,2/2&=3.5 Hz, 1H, H-1/1&), 4.92 (d, J1/1&,2/2& = 3.5 Hz, 1H, H-1/1&), 4.30 (dd, J6a,6b = 
11.7 Hz, J5,6a = 2.2 Hz, 1H, H-6a), 4.07 (dd, J6a,6b = 11.7 Hz, J5,6b = 4.7 Hz, 1H, H-6b), 
4.03–3.99 (m, 1H, H-5), 3.91 (t, J2/2&,3/3& = J3/3&,4/4& = 9.0 Hz, 1H, H-3/3&), 3.90 (t, J2/2&,3/3& = 
J3/3&,4/4 &= 9.0 Hz, 1H, H-3/3&), 3.85 (dt, J4&,5& = 9.6 Hz, J5&,6a& = J5&,6b& = 3.4 Hz, 1H, H-5&), 
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3.71 (dd, J6a&,6b& = 11.7 Hz, J5&,6a& = 3.0 Hz, 1H, H-6a&), 3.69 (dd, J6a&,6b& = 11.7 Hz, J5&,6b& = 
3.9 Hz, 1H; H-6b&), 3.49 (t, J3,4 = J4,5 =9.0 Hz, 1H, H-4), 3.48 (t, J3&,4& = J4&,5& = 9.0 Hz, 1H, 
H-4&), 3.44 (dd, J2,3/2&,3& = 9.0 Hz, J1,2/1&,2& = 3.5 Hz, 1H, H-2/2&), 3.43 (dd, J2,3/2&,3& = 9.0 Hz, 
J1,2/1&,2& = 3.5 Hz, 1H, H-2/2&), 2.36 (dt, J8a,8b = 12.5 Hz, J8a,9 = 7.1 Hz, 1H; H-8a), 2.34 
(dt, J8a,8b = 12.5, J8b,9 = 7.0 Hz, 1H, H-8b), 1.63 (pent, J$,+ = J+,# = 6.8 Hz, 2H, H-9), 
1.38–1.20 (m, 44H, H-10 to H-31), 0.89 (t, J31,32 = 6.8 Hz, 3H, H-32), 0.17, 0.16, 0.15, 
0.14, 0.13 ppm (5*s, 54H, CH3, TMS). All other spectroscopic data and analyses were 
repeated and matched those reported by Stocker et al.118 
 
 
6,6!-Di-O-hexacosanoyl-","!-D-trehalose (27) Dowex-H+ 
(3.0 mg) was added to a solution of TDE 25 (30.0 mg, 0.02 
mmol) in CH2Cl2/MeOH (5 mL, 1:1, v/v), and the reaction 
mixture was stirred at room temperature. After 30 min, the 
mixture was filtered and concentrated in vacuo, and the 
resulting residue was subjected to reversed-phase ODS-C18 
column chromatography (eluting in pyridine) to obtain the 
fully deprotected compound 27 as a white solid (11.18 mg, 0.010 mmol) in 65% yield. 
Rf = 0.52 (EA/MeOH, 95/5, v/v); 1H NMR (500 MHz, C5H5N) ) 5.78 (d, J1,2 = 3.7 Hz, 
2H, H-1), 4.98–4.96 (m, 2H, H-5), 4.87 (m, 2H, H-6a), 4.72 (dd, J6a,6b = 11.7 Hz, J5,6a = 
5.4 Hz, 2H, H-6b), 4.64 (t, J2,3 = J3,4 = 9.0 Hz, 2H, H-3), 4.21 (dd, J2,3 = 9.0 Hz, J1,2 = 
3.7 Hz, 2H, H-2), 4.01 (t, J3,4 = J4,5 = 9.0 Hz, 2H, H-4), 2.23 (dt, J8a,8b = 12.2 Hz, J8a,9 = 
7.5 Hz, 2H, H-8a), 2.17 (dt, J8a,8b = 12.2 Hz, J8a,9 = 7.5 Hz, 2H, H-8b), 1.50 (pent, J$,+ = 
J+,# = 7.4 Hz, 4H, H-9), 1.26–1.04 (m, 88H, H-10–H-31), 0.73 ppm (t, J31,32 = 6.8 Hz, 
6H, H-32); All other spectroscopic data and analyses were repeated and matched those 
reported by Khan et al.28 
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6-O-Hexacosanoyl-","!-D-trehalose (35): Dowex-H+ (0.5 
mg) was added to a solution of TME 33 (5 mg, 0.004 mmol) 
in CH2Cl2/MeOH (0.5 mL, 1:1, v/v), and the reaction 
mixture was stirred at room temperature. After 30 min, the 
mixture was filtered and concentrated in vacuo, and the 
resulting residue was subjected to reversed-phase column 
chromatography (elution with 2% MeOH in H2O) to obtain the fully deprotected 
compound 35 as a white solid (3 mg, 0.004) in 97% yield. Rf = 0.38 (5% MeOH in 
EtOAc); 1H NMR (500 MHz, C5H5N): " 5.84 (d, J1/1&,2/2& = 3.9 Hz, 1H, H-1/1&), 5.82 (d, 
J1/1&,2/2& = 3.9 Hz, 1H, H-1/1&), 5.01–5.91 (m, 1H, H-5), 4.89 (dd, J6a,6b = 11.5 Hz, J5,6a = 
1.9 Hz, 1H, H-6a), 4.89–4.86 (m, 1H, H-5&), 4.73 (dd, J6a,6b = 11.5 Hz, J5,6b = 5.2 Hz, 1H, 
H-6b), 4.70 (t, J2/2&,3/3& = J3/3&,4/4& = 8.9 Hz, 1H, H-3/3&), 4.68 (t, J2/2&,3/3& = J3/3&,4/4& = 8.9 Hz, 
1H, H-3/3&), 4.37 (dd, J6a&,6b& = 11.7 Hz, J5&,6a& = 2.5 Hz, 1H, H-6a&), 4.31 (dd, J6a&,6b& = 11.7 
Hz, J5&,6a& = 4.9 Hz, 1H, H-6b&), 4.22 (dd, J2,3/2&,3& = 9.4 Hz, J1,2/1&,2& = 3.9 Hz, 1H, H-2/2&), 
4.19 (dd, J3&,4& = J4&,5& = 9.4 Hz, 1H, H-4&), 4.18 (dd, J2,3/2&,3& = 9.4 Hz, J1,2/1&,2& = 3.9 Hz, 1H, 
H-2/2&), 4.08 (t, J3&,4& = J4&,5& = 9.4 Hz, 1H, H-4), 2.22 (dt, J8a,8b = 11.5 Hz, J8a,9 = 7.4 Hz, 
1H, H-8a), 2.21 (dd, J8a,8b = 11.5 Hz, J8b,9 = 7.4 Hz, 1H, H-8b), 1.51 (pent, J$,+ = J+,# = 
7.3 Hz, 2H, H-9), 1.27–1.06 (m, 36H, H-10 to H-31), 0.74 ppm (t, J31,32 = 7.1 Hz, 3H, 
H-32). All other spectroscopic data and analyses were repeated and matched those 
reported by Stocker et al.118 
 
 
The TBD and C22 TME were prepared as a side product by Dr. Ashna Khan.  
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General methods and materials for Liposome synthesis: The lipids, L-$-
phosphatidylcholine and cholesterol were purchased from Sigma Aldrich and BDH 
respectively. Chloroform was supplied by Pancreac and Phosphate Buffered Saline 
(PBS) by Invitrogen. Stock solutions of phosphatidylcholine (1 mg/mL) and cholesterol 
(1 mg/mL) in chloroform were prepared in advance and stored at -20 °C under Argon. 
Argon is used to prevent oxidation of phosphatidylcholine. A stock solution of C26 
TDE (1 mg/mL) was also prepared in CHCl3/EtOH (1:1, v/v) and stored under Argon. 
The preparation of the liposomes was performed in a similar way as previously 
described by van Rooijen et al. via the dried-lipid film hydration method,96 followed by 
sonication. Here, cholesterol and phosphatidylcholine (5.3:1 molar ratio) were dissolved 
in cholorform. A dried lipid film was obtained by evaporation of organic solvents under 
reduced pressure at approximately 45 oC for 30 minutes. The lipid layer was dispersed 
with phosphate buffer solution (PBS) by gentle rotation for 2 h at RT. The resulting 
suspension was then gently shaken and sonicated in a waterbath at 40 Hz (Ultrasonic 
cleaner FXP8M) for 3 min. The liposome suspension was held under argon gas 
overnight at 4 oC and used within 3 days.  A representative experiment for each different 
liposome formulation is given below. 
 
 
Procedure for empty PC/cholesterol liposomes: 8.07 mL (8.07 mg, 10.3 !mol) of 
phosphatidylcholine stock solution was added to 0.75 mL (0.75 mg, 1.94 !mol) of 
cholesterol stock solution in a 500 mL round bottom flask. The chloroform was removed 
by low vacuum (minimum 120 mbar) evaporation, to give a white phospholipid film that 
formed against the inside of the flask. The lipid film was then dispersed in 3 mL PBS by 
gentle rotation (maximum 180 rpm) at RT for 30 min. The resulting milky white 
suspension was then held under nitrogen gas at RT for 2 h, then shaken gently and 
sonicated in a water bath for 3 min. This suspension was then stored under nitrogen gas at 
RT overnight at 4 °C to allow for the swelling of the liposomes. The suspension is 
gently shaken before administration to cells or before diluting, in order to achieve a 
homogeneous distribution of the liposomes in suspension. 
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General Procedure for TDE containing liposomes: The preparation of TDE 
containing liposomes follows the procedure of empty PC/cholesterol liposomes, as 
described above. Additionally, a known quantity (see below) of TDE was dissolved in 
CHCl3/EtOH (1:1, v/v), and added to the mixture of PC and cholesterol in chloroform, 
before evaporation of organic solvents under reduced pressure to give a dried lipid film. 
The resulting lipid film was then re-dissolved in CHCl3 and co-evaporated twice with 
CHCl3 to ensure complete removal of EtOH. Dispersion of the lipid film was then 
achieved, as previously described. 
 
For 3.4.2.2: 4% weight loading of C26 TDE in liposome (actual: 2.5%): 
C26 TDE (0.537 mg, 0.488 !mol) dissolved in 1:1 CHCl3/EtOH was added to the 
mixture of PC (8.07 mg, 10.3 !mol) and cholesterol (0.75 mg, 1.94 !mol) in 
chloroform.  
 
For 3.4.2.2: 8% weight loading of C26 TDE in liposome (actual: 5.4%): 
C26 TDE (1.07 mg, 0.976 !mol) dissolved in 1:1 CHCl3/EtOH was added to the 
mixture of PC (8.07 mg, 10.3 !mol) and cholesterol (0.75 mg, 1.94 !mol) in 
chloroform.  
 
For 3.4.2.1 and 3.4.2.2: 16% weight loading of C26 TDE in liposome (actual: 
7.6%): 
C26 TDE (2.146 mg, 1.952 !mol) dissolved in 1:1 CHCl3/EtOH was added to the 
mixture of PC (8.07 mg, 10.3 !mol) and cholesterol (0.75 mg, 1.94 !mol) in 
chloroform. 
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Quantification of TDE content in liposomes: The amount of C26 TDE incorporated 
into the liposomes was determined by measuring the carbohydrate content in aqueous 
soultion using the phenol–sulfuric acid method.122 The liposomes were pelleted by 
centrifugation at 10,000 RPM for 10 min and the PBS was removed using a glass pipette 
without disrupting the pellet. The liposomes were then resuspended in distilled water to 
a concentration of 0.5 mg/mL, and titrated down in 2-fold dilutions in triplicates into a 
96-well plate. The 50 µL aliquot of a liposome suspension solution is mixed with 150 
µL of concentrated sulfuric acid. Subsequently, 30 µL of 5% aqueous solution of phenol 
is added rapidly to the mixture in a 96 well plate. After the plate is vortexed for 30 s, the 
plate is placed for 10 min at room temperature in the dark for color development. Then, 
light absorption at 490 nm is recorded on a Titertek Multiscan microplate reader (Flow 
Laboratories, North Ryde, Austral). Reference solutions are prepared in an identical 
manner as above, except that the 50 µL aliquot of liposomes is replaced with distilled 
water. The 5% phenol in water (w/w) was prepared immediately before the 
measurements. The standard curve of !,!"-trehalose (in distilled water) was fitted with a 
line of best fit to give an equation, y = -1.2171x2 + 1.4703x – 0.0097 (R2 = 0.99365). 
This equation allowed the corresponding amount of C26 TDE in the liposomes to be 
determined. 
 
 
Measurement of liposome size: Size and size distribution measurements were performed 
in triplicate by dynamic light scattering (DLS) using a Zetasizer Nano ZS (Malvern 
Instruments Ltd, Malvern, Worcestershire, UK) at 25 °C. Calculations of size distribution 
based on light scattering intensity were performed by the Zetasizer Nano ZS software from 
the correlation functions using the General Purpose algorithm (Malvern Dispersion 
Technology Software). Size measurements were made on the neat liposome suspension 
and also in samples, which were diluted by a factor 4 with a solution of PBS buffer 
before size measurements performed by DLS. The neat suspensions and dilutions were 
measured three times each. 
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General methods and materials for biological assays: C57BL/6 mice and the  
Mincle-/- mice were bred and housed in a conventional animal facility at the Malaghan 
Institute of Medical Research, Wellington, New Zealand. All animals used for the 
experiments were aged between 8-10 weeks. All synthetic compounds were confirmed 
to be free of endotoxin, at a sensitivity of , 0.125 EU/mL by testing them in Limulus 
amebocyte lysate (LAL) assay using an endotoxin kit (Pyrotell, Limulus Amebocyte 
Lysate).  
 
 
Generation of bone marrow derived macrophages (BMMs): Mice were culled in an 
enclosed CO2 chamber, and the legs and muscle were removed by dissection. Bone 
marrow cell suspensions were isolated by flushing femurs and tibias of 8- to 12-week-
old C57BL/6 mice with Iscove's modified Dulbecco's medium (IMDM, Gibco) 
Aggregates were dislodged by gentle pipetting, and debris was removed by passaging 
the suspension through a 70 !m nylon cell strainer. The cell suspension was spun in the 
centrifuge at 1000 RPM for 10 min, resuspended in 10 mL ACT buffer and incubated at 
37 oC for 5 min to lyse red blood cells. After this time, 10 mL of IMDM was added to 
the suspension and the cells spun in the centrifuge at 1000 RPM for 10 min. Cells were 
adjusted in IMDM medium supplemented with FBS (Gibco, 5%), penicillin 
streptomycin (Gibco, 1%) and 2-mercaptoethanol (Invitrogen, 55 µM) containing GM-
CSF (clone X63/GM-CSF murine cells, 10 ng/mL'1), to give a suspension of 250 000  
cells/mL, and seeded on 24-well plates. Cells were cultured in a humidified incubator at 
37 °C (5% CO2) and the media changed on days 2, 5 and 7. On day 10, the media was 
removed and the BMMs were either primed with IFN-# (10 ng/mL'1, Peprotech) for 3 h 
prior to the addition of the compounds (Experiments described in section 2.4) or 
liposomes. 
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BMM Assay: TDE and TME solutions were prepared (2.5 mg/mL in PBS containing 
2% DMSO), vortexed and warmed to 50 °C for 30 min (x 3) to ensure complete 
solubilisation of the compounds prior to administration to BMM cultures. BMM 
cultures were then treated with a known amount of TDE incorporated liposomes or 20 or 
40 µg/mL of TDE, TME, with LPS (100 ng/mL) as a positive control and media only as 
a negative control for the times indicated. Supernatants were collected and tested 
immediately for NO levels or stored at -80 °C for subsequent cytokine analysis.  
 
 
Quantification of NO: NO production in supernatants was evaluated by measuring the 
accumulation of NO in the culture medium by using Griess reagent (modified, Sigma 
Aldrich) containing 1% sulphanilamide in 5% H3PO4 and a 0.1% solution of N-1-
naphthylethylene diamine hydrochloride. The mixture of Griess reagent and the culture 
supernatuant at a 1:1 ratio was incubated at 15 min at room temperature in the dark, and 
the optical denisty (OD) was determined at 550 nm with a plate reader. Liposome-
treated macrophage supernatants were collected at different time points. The culture 
supernatant were analysed for their NO contents by using the in the Griess assay.135 
 
 
Statistical Analysis: All experiments were carried out three times, and only 
representative data are presented. All graphs and statistical analyses were generated in 
GraphPad Prism (GraphPad Software Inc., San Diego, CA, USA). A nonparametric 
unpaired t test was used for analysis. Data was considered statistically significant when 
p < 0.05. Error bars indicate ± standard errors of the means (SEM). 
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